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Exosomes Secreted under Hypoxia Enhance Stemness in
Ewing’s Sarcoma and Transform Microenvironment Cells
Matthew J. Kling, Ph.D.
University of Nebraska Medical Center, 2020
Supervisor: Shantaram S. Joshi, Ph.D.
Intercellular communication between tumor cells and stroma within the hypoxic
microenvironment promote aggressiveness and poor patient prognoses in ways that
remain unclear. Here we show that hypoxic Ewing’s sarcoma (EWS) cells release
exosomes that promote sphere formation, a stem-like phenotype, in EWS cells by
enhancing survival and a cancer-associated phenotype in fibroblasts (CAFs). Given that
hypoxia enriches for stem-like cells, we exposed EWS cells to hypoxia and hypoxic
EWS-derived exosomes and assessed the stem cell phenotype. Hypoxia and hypoxic
EWS-derived exosome were found to enhance TIC formation in vitro and in vivo by
reprogramming EWS cells. Analysis of the hypoxic exosomal miRNA cargo identified a
HIF-1α regulated miRNA, miR-210, as a potential mediator of sphere formation in cells
exposed to hypoxic exosomes. Knockdown of HIF-1α in hypoxic EWS cells led to
decreased exosomal miR-210 levels and reduced the capacity of hypoxic exosomes to
form spheres. Inhibition of miR-210 in hypoxic spheres attenuated sphere formation and
overexpression of miR-210 in normoxic spheres significantly enhanced the number of
EWS spheres. Our results indicate that hypoxic exosomal miR-210 targets the
proapoptotic protein CASP8AP2 in recipient cells. Moreover, the suppression of
CASP8AP2 led to a reduction in apoptotic cells and increased sphere formation.
Exosomes co-cultured with fibroblasts in a soft agar assay and 2D culture
assessed induction of the CAF phenotype. Fibroblasts preconditioned with exosomes
were injected into NSG mice to determine the effects of exosomes on tumorigenicity.
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Exosomes increased expression of CAF markers and tumorigenicity in fibroblasts.
Network analysis of hypoxic-derived exosomes revealed enrichment of miRNA targeting
the Akt pathway. Our observations suggest that hypoxic-derived exosomes enhance an
aggressive phenotype in EWS and fibroblasts by increasing Akt signaling.
Together, the findings in this study suggest that hypoxic exosomes promote
stemness in EWS cells by delivering enriched miR-210 that is capable of downregulating apoptotic pathways, resulting in the survival of cells with increased sphere
formation. Future studies will further investigate the effect of exosomal miRNA on target
genes and the role these interactions play in driving aggressiveness in hypoxic EWS
cells. Future work will investigate the role of exosomal miRNA on the Akt pathway in
target cells.
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Chapter I
Introduction
Ewing’s sarcoma Introduction
Ewing’s sarcoma (EWS) is an aggressive and highly malignant tumor that
belongs to a family of tumors that include primitive neuroectodermal tumors, Askin’s
tumors, and extraosseous Ewing’s sarcoma. The tumor was first described by James
Ewing in 1921 as sheets of small round blue cells (1). In 85% of clinical cases, EWS
tumors arise in bone localized primarily in the pelvis, diaphysis of long bones, the ribs
and sternum. Fifteen percent of the cases are formed at extraoseous sites within soft
tissues of the thoracic region, proximal limbs, bladder, kidney, prostate, paravertebral
space and the meninges. The majority of patients afflicted with EWS are diagnosed
between 10-20 years of age with a peak incidence of 15 years (2-4). The frequency of
EWS are 1 to 3 per million per year and is more common in people of European descent
with a minor predominance in males. Ewing’s sarcoma is the second most prevalent
malignant bone tumor in children and adolescents, but is considered to have the worst
prognosis of the bone sarcomas (5, 6). The current 5-year survival rate has increased in
recent years ranging from 59% to 78% in children under 15 years of age and 20% to
60% for adolescents over the age of 15 years, however, the 5-year survival rate patients
diagnosed with metastasis or undergo relapse is less than a 25% (7).
Histologically, EWS tumors share the common round blue cell morphology with
other tumors which include neuroblastoma, alveolar rhabdomyosarcoma and
lymphoblastic lymphoma (8). The high expression of the cell adhesion transmembrane
glycoprotein, CD99, in these tumors served as an immunohistochemical diagnostic
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marker for EWS but had low specificity due to their common expression (9, 10). In the
past, this lead to diagnosis by exclusion until the discovery of the chromosomal
translocation t(11;22)(q24:q12) and its EWS-FLI1 fusion protein which occurs in 85% of
EWS (11, 12). This provided a more definitive diagnostic marker through molecular
analyses. In the past, the correct cell of origin was a subject of great debate between
primitive neuroectodermal cells (13) and mesenchymal stem cells. Studies supporting a
mesenchymal origin indicated a primordial bone marrow derived mesenchymal stem cell
(14). Riggi et al. demonstrated transformation of mesenchymal progenitor cells by
introducting a retrovirus containing the fusion gene into murine MPC (15). In this study,
the round blue cell phenotype was maintained along with upregulation of known EWSFLI1 target genes.
This review will focus on the many aspects of ESFTs which include: the role of
EWS-ETS fusion proteins and their constituents, the oncogenic role of the fusion
proteins, the role of microRNAs and novel therapeutic targets in Ewing’s sarcoma.

EWS-ETS Fusion Proteins
ESFTs are characterized by a chromosomal translocation involving the EWSR1 (Ewing’s
sarcoma breakpoint region 1) gene and the ETS (E26 transformation-specific) family of
genes (11) (Figure 1.1). The most common translocation in 85% of patients afflicted with
ESFT includes the fusion of EWSR1 located on chromosome 22 band q12 and ETS
family member FLI1 (Friend leukemia integration 1 transcription factor) located on
chromosome 11 band q24 (11). The result of this translocation, t(11;22)(q24;q12), leads
to the EWS-FLI1 chimera protein that functions as an aberrant oncogenic transcription
factor (16-18). The N-terminal domain of EWS encompasses a potent transcriptional
activation domain juxtaposed to the DNA-binding C-terminal domain of FLI1 (16, 19, 20).
EWS-FLI1 isoforms exist in tumors which consist of translocations that combine a
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Figure 2.1: Schematic of most common EWS-FLI1 chromosomal translocation
t(11;22)(q24:q12). Exons are denoted by black and white boxes. EWS and FLI gene
breakpoint regions are indicated by EWSR1 and EWSR2, respectively. EWS-FLI1 fusion
protein domains: SYQG, serine-tyrosine-glutamine-glycine rich regions (transactivation
region); DNA-BD, DNA binding domain; Pro, proline-rich (activation domain). Image
adapted from Delattre et al., 1994 New England Journal of Medicine 331:294-9 and
Janknecht, 2005 Gene 363:1-14.
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Figure 1.2: Outline of EWS and five ETS proteins (FLI1, ERG, FEV, ETV1, ETV4)
that participate in Ewing’s sarcoma translocations. Arrows indicate observed
breakpoints in EWS-ETS fusions. Image adapted from Janknecht, 2005 Gene 363:1-14.
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truncated form of EWS at exons 7, 8, 9, or 10 to exons 5, 6, 7, or 8 of FLI1 (21), leading
to chimeric variants which include the first 264 to 348 residues of EWS being fused to
the last 191 to 324 residues of FLI1 (11). Breakpoints in the gene locus are in a small 8
Kb region in the EWSR1 gene as opposed to the larger 35 Kb region in the FLI1 gene
(11). Research suggest that the amino and carboxy termini of EWS-FLI1 are integral for
efficient cell transformation (16, 17). Different EWS-FLI1 isoforms have been shown to
determine its transactivation potential which correlates with patient prognoses (21, 22).
Tumorigenesis mediated by EWS-FLI1 has been shown to take place through DNA
binding directly and indirectly, indicating that cell transformation was not completely
dependent on DNA binding (23). Knockdown studies elucidated the oncogenic behavior
of EWS-FLI1 showing growth inhibition, increased ability to undergo apoptosis,
abolishment of anchorage-independent growth and attenuation of tumor formation in
nude mice (8).
In EWS, other chromosomal translocations occur in 15 % of cases that involve
the ESWR1 gene binding ETS family members ERG (~10%) (24), ETV1 (<1%) (25),
ETV2 (<1%) (26), FEV (<1%) (27) (Figure 1.2). These translocation variants result in
fusion proteins that play a similar role as EWS-FLI1, but may vary in their ability to
regulate gene transcription and transform cells (18).

EWS Gene
EWSR1 encodes the EWS protein which becomes fused to FLI1 in the majority
of EWS cases (11). EWS contains an RNA recognition motif (RRM) and three regions
rich in arginine-glycine-glycine (RGG) which are implicated in protein RNA-binding (11,
19). EWS has a zinc finger domain that may bind DNA, but most importantly, it contains
a potent transcription activation N-terminal domain rich in serine-tyrosine-glutamineglycine that is active when fused to a DNA-binding domain (16, 17, 28). EWS belongs to
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the TET family of RNA-binding proteins that include TLS (translocated in liposarcoma)
and TAF15 (TATA-binding protein associated factor 15) (29) TET family members have
a high degree of homology and are involved in chromosomal translocations seen in
various diseases such as EWS (EWS-ETS), myxoid liposarcoma (TLS-CHOP) and
myxoid chondrosarcoma (TAF15-CHN) (11, 30). Multiple studies have shown that both
TLS and EWS are post-translationally modified by Ser./Thr. protein kinases, such as
PKC, and it is thought that this regulates their subcellular localization to the nucleus (31,
32). The N-terminus of EWS along with the other TET proteins are thought to function in
RNA polymerase II (RNA pol II) transcription by interacting with RNA pol II subunits and
TFIID (33). It has been shown that EWS-FLI1 may interact with similar RNA pol II
subunits as EWS (34). Many experiments have suggested that TET proteins play a role
in pre-mRNA splicing. This was confirmed by mass spec analyses. EWS and TLS
carboxy terminal domains were found to interact with splicing activator YB-1. These
studies suggest that TET proteins have a role as adapters between transcription and
mRNA processing (35, 36).

FLI 1 Gene
FLI1 gene encodes the FLI1 protein which is the main fusion partner of EWS in
EWS (11). FLI1 belongs to the highly homologous ETS family of transcription factors and
is thought to have a role in oncogenesis (37). The N-terminal domain of FLI1 consists of
the proline rich region that serves as a weakly- transactivating domain (NTA) that is
displaced by EWS in the fusion protein. A strong DNA-binding domain is present at the
C-terminal end of FLI1 along with another proline rich transcription activation domain
(CTA) (38). Transcriptional activation or repression takes place in part when FLI1 or
EWS-FLI1 recognizes a small core GGAA/T DNA sequence in the genome (39). Early
on in embryonic development, FLI1 is expressed as a nuclear protein in mesenchymal
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cells of neural crest and mesodermal origin (40-42). As an adult, FLI1 is expressed in
hematopoietic cells located primarily in the thymus and the spleen due to expression in
megakaryocyte, lymphocytes and erythroid precursors (43). Deletions of FLI1 locus in
mouse studies was embryonically lethal resulting in intra-cranial hemorrhaging and
defective megakaryopoiesis (44, 45). These studies suggested that FLI1 plays a role in
hematopoietic development. The oncogenic role of FLI1 was revealed in an animal
model overexpressing FLI1 resulting in B cell proliferation, hypergammaglobulinemia
and an autoimmune disorder (46). This confirmed FLI1s role in vasculogenesis. Further
elucidation of FLI1s role in transformation and oncogenesis demonstrated FLI1 to inhibit
expression of tumor suppressor retinoblastoma proteins (37). Cell survival is enhanced
in erythroid cells by induction of Bcl2 expression by FLI1 (47). These studies show FLI1s
ability to promote cell transformation and tumorigenesis.

EWS-FLI1 Targets
The fusion protein is an oncogenic transcription factor with a potent
transactivation domain fused to a DNA binding domain. EWS-FLI1 is able to modulate
gene expression, thereby repressing or upregulating gene transcription leading to EWS
formation (48). A myriad of genes have been identified through various knockdown
studies and ChIP analysis demonstrating modulation by EWS-FLI1 (49). Binding to the
gene promoter region by EWS-FLI1 can take place through direct DNA binding or
through indirect binding via protein-protein interactions. To understand the mechanism of
EWS-FLI1 driven pathogenesis, one must elucidate gene targets and protein-protein
interactions. Target gene promoters have been shown to contain tandem binding sites
for the ETS portion of the EWS-FLI1 and AP-1 proteins such as Fos-Jun dimers. The
cooperative binding between the C-terminal portion of the fusion protein and Fos-Jun to
promoter regions was found to be essential for EWS pathogenesis (50). This suggests
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that the carboxy terminus of EWS-FLI1 not only interacts with DNA regulatory elements,
but binds with other transcriptional regulators to promote oncogenesis. In addition to
interacting with Fos-Jun, other basal transcriptional apparatus binding partners include
CBP/p300 (51), BARD1 (52), RHA (53), NR0B1/DAX1 (54), TFIID (55) and RNA Pol II
subunits hRPB3 and hRPB7 (34, 55).
Direct gene targets of EWS-FLI1 revealed by ChIP analysis contributes to EWS
development. Downregulation of TGF-βRII by the fusion protein at its promoter region
has been shown to contribute to helping EWS cells evade growth inhibition (56). Knockdown studies revealed EWS-FLI1 transcriptional repression of IGFBP-3 leading to
increased cell survival by activating the Akt signaling pathway (57). Upregulation of Id2
by EWS-FLI1 may lead to the undifferentiated state of ESFT cells by interacting with the
transcription factor E2A and, in turn, suppressing its DNA binding capability (58, 59). Cell
growth and modulation of sensitivity to cytotoxic drugs is affected by the overexpression
of PTPL1 in EWS (60). Downregulation of PLD2 by EWS-FLI1 correspondingly lead to
decreased PDGF signaling, therefore, resulting in inhibited cell proliferation (61). Other
direct targets of the fusion protein include Aurora kinase A, caveolin, GSTM4, GLI1,
EZH2, uridine phosphorylase, PDGF-C, CCND1, MYC, p21, p57, hTERT, VEGF, EAT-2,
mE2-C, MFNG, DAX1 and NKX2-2 (49).
The disordered nature of the fusion protein facilitates the formation of nuclear
complexes that can modulate gene expression through both mRNA synthesis and
splicing (62, 63). EWS-FLI1 interacts with part of the spliceosome and has been shown
to regulate posttranscriptional splicing. The spliceosomal component U1C was identified
as a protein partner in a yeast two hybrid approach experiment (62). In this study, EWSFLI1 was demonstrated to alter the splicing site of E1A mRNA modifying its functionality.
Other proteins such as TASR and YB-1 have been shown to be involved in the EWS-
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FLI1 spliceosomal complex, but further research is needed to identify the spliceosome
conformation (36, 64). A mechanism for modulation of gene expression may couple
transcription initiation by the RNA Pol lI interaction with mRNA splicing. EWS-FLI1 could
potentially accompany RNA Pol II during transcription and simultaneously alter those
transcripts through its interaction with the spliceosome.

Role of miRNAs in EWS
MicroRNA (miRNA) are small, 20 to 30 nucleotide, non-coding RNAs that
regulate gene expression through post-transcriptional modifications (65). One-third of
the human genome has been estimated to be regulated by ≈1500 miRNAs (66).
Silencing of mRNA translation occurs through miRNA selectively binding to a ~6-8
nucleotide sequence in the 3` UTR region on the target mRNA (65). miRNAs play a role
in regulating normal cell function, development, embryogenesis, cell fate and
maintenance of the cell (67-72). Due to miRNAs functions in carcinogenesis as tumor
suppressors or oncomeres, therapeutically this presents a novel focus for determining
prognostic markers and treatments for EWS patients (73, 74).
MiRNA processing begins with RNA polymerase II transcription resulting in long
precursor miRNAs called pri-miRNAs. These pri-miRNA transcripts possess the
sequence for one or more mature miRNAs that can arise from either protein coding
genes or non-protein coding transcripts (75). Once pri-miRNA transcripts are generated,
they fold into a stem-loop hairpin structure that is ~70 nucleotides long. This hairpin
structure is stabilized by an RNA binding complex Drosha and DGCR8 where it is then
cleaved by Drosha, generating pre-miRNA (75). The nuclear transporter, Exportin 5,
assists in the diffusion of pre-miRNA from the nucleus to the cytoplasm (76). Dicer, with
the help of TRBP, interacts with the pre-miRNA where further processing takes place
resulting in a double-stranded miRNA (77). One of the two strands is selected to form
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the RISC complex which contains the single miRNA strand bound to the Argonaute
protein (78). This newly formed miRNA-RISC complex is able to inhibit protein
expression through translational repression by targeting mRNAs 3’UTR or inducing
mRNA degradation through an unknown mechanism (78). Understanding miRNA
processing will most likely provide a window into how miRNAs are dysregulated in
cancer and potentially lead to prevention and treatment of EWS. The interaction
between the fusion protein and RNA pol II may lead to transcriptional repression of some
miRNAs and potentially a gain of function of other miRNAs resulting in the oncogenic
effects in EWS (79). Downregulation of TRBP, resulting in decreased levels of mature
miRNA, has been shown in EWS and it has been theorized that TRBP may be a target
of EWS-FLI1 (80).
EWS-FLI1 has been shown to potently induce miRNA expression profile
differences, especially in miRNA-145 and let7a (80). Numerous miRNA expression
profiling studies have been performed by knocking-down EWS-FLI1. In Ewing’s
sarcoma, miRNA expression was found to be deregulated in miRNA expression profile
studies compared to controls (79, 81, 82). However, these studies revealed difference in
expression profiles which may be a result of knock-down methods amongst other
experimental design discrepancies. EWS-FLI1 and miRNA-145 were demonstrated to
have an important role in EWS cell differentiation and tumor development (80). This was
shown when EWS-FLI1 was introduced into human pediatric mesenchymal stem cells
(hpMSC), resulting in miRNA-145 repression and induction of the EWS phenotype (80).
Both EWS-FLI1 and miRNA-145 function in a reciprocating repressive feedback loop
(80). SOX2, a target gene of EWS-FLI1 and miRNA-145 expressed in embryonic stem
cells, was expressed in hpMSC upon induction of EWS-FLI1 (80). This may be a
potential mechanism for EWS pathogenesis. Furthermore, Ban et al. confirmed EWS-
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FLI1 and miRNA-145 are involved in a positive feedback loop and went on to show that
miRNA-145 modulates the fusion protein by targeting the FLI1 3` UTR (81). Repression
of let7a by EWS-FLI1 contributes to the tumorigenicity in EWS (80). Overexpression of
let7a in in vitro studies revealed HMGA2 translational repression resulted in decreased
EWS cell proliferation (80). Synthetic delivery of let7a in EWS bearing mice inhibited
EWS growth by regulating HMGA2 (79). These studies demonstrated that a small group
of downregulated miRNAs in EWS are responsible for reducing expression of prooncogenic targets in the IGF pathway (79).
Knock-down studies involving manipulation of EWS-FLI1 have demonstrated
dysregulation of a myriad of miRNAs (79, 81, 82). This suggests that miRNAs have
tumor suppressor and oncogenic functions that contribute to tumorigenesis of EWS.
Functional analysis of miRNA34a, miRNA-31a, miRNA-125b and miRNA30a-5p have
elucidated the impact that miRNA dysregulation can have on EWS pathogenesis.
Overexpression of miRNA-34a in EWS cell lines demonstrated increased sensitivity to
chemotherapy drugs and reduced the proliferative and malignant capabilities of the EWS
cells (83). Nakatani et al. revealed miRNA-34a as an important prognostic marker in
patient samples. Patients with increased miRNA-34a expression were relapse free for
five years, but patients with downregulated levels of miRNA-34a were shown to have a
recurrence within two years (83). Comparison of expression profiles of miRNA-31a in
EWS cells and mesenchymal stem cells revealed decreased transcripts in EWS cells.
When overexpressed in EWS cells, miRNA-31a contributes to increased apoptosis and
decreased proliferation (84). MiRNA-125b has been shown to have both a tumor
suppressive role and an oncogenic role. In A673 cells that have a type I fusion gene
variant, miRNA-125b exhibits decreased expression levels. When overexpressed in
A673 cell lines, there is a decrease in proliferation, migration, invasion, cell cycle arrest,
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and increased apoptosis (79, 81, 82). MiRNA-125b was found to be upregulated in
doxorubicin-resistant EWS cell lines. Knockdown of miRNA-125b increased sensitivity to
doxorubicin in EWS cells; while studies overexpressing miRNA-125b demonstrated
enhanced chemotherapeutic resistance (85). Franzetti et al. demonstrated the
downstream effects of depleting EWS-FLI1 in A673 cells showing downregulation of
miRNA-30a-5p (82). Overexpression of miRNA-30a-5p inhibited proliferation, invasion
and CD99 in A673 cells (82). This study provided a link between the fusion protein and
CD99.

Novel Theraputic Targets in EWS
Current treatment regimens of EWS include chemotherapy, radiation and
surgery. The use of adjuvant chemotherapy following surgery and/or radiation resulted in
significant improvements in outcomes (86). In the 1990s, ifosfamide and etoposide were
added to the chemotherapeutic regimen, which already included vincristine, actinomycin
D, cyclophosphamide and doxorubicin (87). Since then, the five year survival rate of
EWS patients is ~60-70% when diagnosed with non-metastatic carcinomas and ~30%
in patients that present with metastases at diagnosis (7). With these advances in
treatment, EWS still has the worst prognosis of the bone sarcomas. The risk of
developing a secondary malignancy, such as acute myeloid leukemia and
myelodysplastic syndrome, is relatively high with the use of chemotherapy and radiation.
The severity of these side effects using traditional therapies provides sufficient evidence
that targeted therapeutic strategies must be developed.
The unique translocation resulting in EWS-FLI1 has been identified as a
significant driver in EWS pathogenesis (16, 19, 88). Expression of EWS-FLI1 has not
been demonstrated in any other cells other than EWS (89). Targeting EWS-FLI1 with
antisense oligonucleotides, antisense RNA expressed from a vector and siRNA
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delivered via nanoparticles inhibits EWS proliferation in cell lines and xenograft models
(90, 91). Clinical implementation of this approach has proven to be a challenge due to a
lack of efficient pharmacologic delivery mechanisms.
A more feasible approach may lie in disrupting interactions between EWS-FLI1
and its protein partners with small molecule inhibitors. The development of YK-4-279, a
compound that blocks the interaction between EWS-FLI1 and RHA, was shown to
decrease tumorigenic effects by inducing apoptosis in cell lines and inhibiting growth in
xenograft models (92).
The use of small molecule inhibitors provides a novel approach to treating EWS.
Overexpression of IGF-1R has been shown to promote cell growth and tumorogenesis.
IGF-1R mediated signaling has been observed in EWS cell lines and tissue samples
(93). The development of inhibitors targeting IGF-1R demonstrated toxicity in part
because it acted on proximal portions of the signaling cascade. Combination of IGF-1R
inhibitors and chemotherapy drugs may be a suitable therapeutic option. Knockdown
studies inhibiting expression of the fusion protein in cell lines augmented p53 signaling
activity (94, 95). This suggested EWS-FLI1 plays a role in repressing the tumor
suppression activity of p53. Inhibitors Nutlin-3a, MI-219, Tenovins and actinomycin D
have shown to stabilize and enhance p53 activity (96, 97). Rapamycin inhibits mTOR,
the downstream effector of the PI3K-Akt signaling pathway, which mediates escape from
apoptosis and cell proliferation (98). In EWS patients, the PI3K-Akt pathway may be
over activated leading to disease development and progression (99). mTOR inhibitors
block proliferation in EWS cell lines by arresting the cell cycle and concomitantly
decreasing EWS-FLI1 levels (100). Inhibition of VEGF was shown to block the
tumorigenic effects in EWS cell lines (101). Treatment with bevacizumab, a small
molecule directed at the VEGF receptor, has been suggested, but the potential side
effects to inhibiting VEGF signaling could disrupt angiogenesis in developing children
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and adolescents, which could have deleterious effects during the maturation process.
The receptor tyrosine kinase KIT and its ligand promote cell growth and cell survival in
EWS cell lines (102, 103). The use of imatinib has been suggested to target the
oncoprotein KIT. miRNA based therapeutics introduces promising candidate molecules
such as miRNA-145, miRNA-143 and TRBP2 (80, 104).
The use of monoclonal antibodies targeting EWS-FLI1 has not been proven to be
effective due to the disordered nature of the fusion protein. However, antibodies
targeting proteins involved in EWS pathogenesis are a more likely therapeutic approach.
Monoclonal antibodies directed at CD99 induce apoptosis in cell lines and slowed tumor
progression in a xenograft model (105). A synergistic effect was seen when combined
with doxorubicin and vincristine leading to enhanced growth inhibition (106). A less toxic
approach targeting IGF-1R is being investigated using monoclonal antibodies
Cixutumumab and Dalotuzumab. Both were both shown to inhibit IGF signaling and cell
proliferation (107, 108).

The Origin of Ewing’s sarcoma and the discovery of the tumor-initiating
cell
The cell of origin in EWS has remained elusive to investigators, however, along
the path to determining a potential cell of origin, there have been some enlightening
discoveries regarding cells permissive to EWS-FLI1 transformation and EWS
subpopulations with TIC capabilities. In this section, I will describe the important studies
that have contributed to determining the origin of EWS and the discovery of EWS TICs
that partially resulted from this endeavor.
The largest gap in understanding EWS pathogenesis for the past two decades
has been in elucidating a cellular origin that can be adapted to an animal model.
Recently, a CRISPR/Cas9 approach was utilized to generate the chromosomal
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translocation t(11;22) in stem cells resulting in the most common EWS fusion transcript
(109), EWS-FLI1, however, the approach has not been translated to an animal model,
nor has it lead to revealing a cell of origin that capitulates EWS tumorigenesis.
Histological observations of EWS tumors demonstrated a poorly differentiated
phenotype with a morphology described as having sheets of round blue cells when
stained with PAS (8). Early studies using immunohistochemistry indicated
neuroectodermal and mesenchymal features based on surface marker expression
profiles (8). Initially, NIH3T3 murine embryonic fibroblasts were transformed with EWSFLI1 resulting in anchorage independent growth using a soft agar assay and increased
tumorigenesis in mice compared to NIH3T3 control cells (110). In this model and others,
functional IGF1R signaling was shown to be an early requirement for EWS-FLI1
mediated transformation (15, 110). Subsequent studies transducing human primary
fibroblasts with the EWS-FLI1 fusion gene lead to induction of p53-dependent growth
arrest and apoptosis. Further studies demonstrated that deletion of p53, p19ARF and
p16INK4A allowed stable EWS-FLI1 expression in fibroblasts (15).
The continued search for a cell permissible to stable EWS-FLI1 expression
found murine mesenchymal progenitor cells (MPCs) as a viable cell suitable for the
fusion gene (15). Here, MPCs were isolated from the bone marrow of C57BL/6 mice and
transduced with EWS-FLI1. MPCs expressing the fusion gene formed tumors in mice
that had a round blue cell phenotype. The tumors expressed the EWS marker CD99 in
the context of functional p53 and p19ARF expression. Stable expression of EWS-FLI1 in
the presence of p53 and p19ARF previously prevented transformation and lead to
apoptosis in primary fibroblasts. Similar to the findings in transformed NIH3T3 cells,
these EWS-FLI1 expressing murine MPCs demonstrated significantly elevated IGF1
expression and upregulated IGF1R signaling. These findings provided the basis to
proceed to transducing human MPCs with the fusion gene (15).
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The findings in human mesenchymal stem cells (hMSCs) transduced with EWSFLI1 (111) were very similar to the observations in transformed murine MPCs (15).
Induction of CD99 was reported along with increased IGF1R signaling (111). Moreover,
the studying found that these transformed cells maintained trilineage differentiation
potential and upregulation of genes implicated in neural crest and neuronal development
which supports the neuroectodermal origin hypothesis. A major roadblock to supporting
hMSCs as the cell of origin for EWS was encountered when the EWS-FLI1 expressing
hMSCs failed to form tumors in mice. However, there were significant similarities in the
gene expression profile with primary EWS tumors. These observations demonstrated a
shared gene program between EWS tumors and hMSCs induced with EWS-FLI1, which
prompted this same group to explore permissibility in pediatric hMSCs, since EWS
develops in children and young adults, and the hMSCs that they were using were from
older patients. An interesting finding in this study, however, elucidated EZH2 expression
was significantly increased in EWS-FLI1 expressing hMSCs . Importantly, EZH2
functions as a histone methyltransferase within the polycomb repressor complex 2 and
has been described to be crucial for self-renewal and differentiation. This discovery
suggested the potential emergence of a cancer stem cell phenotype that was pursued in
subsequent studies by the Riggi lab.
The cancer stem cell population in EWS was discovered by probing for the
cancer stem cell marker CD133 (14). The small EWS subpopulation expressing CD133
on their surface was sorted using a fluorescently tagged antibody recognizing the CD133
epitope on EWS primary cells. Serially xenotransplanting CD133+ and CD133- cells in a
limiting dilution approach revealed that only CD133+ EWS cells could form tumors in
mice. Tumors derived from CD133+ cells were analyzed by FACS and it was observed
that the tumors retained their small subpopulation of CD133+ cells, while giving rise to a
bulk tumor with a CD133- cell population. FACS analysis combined with serially
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transplanting these cells two more times in NSG mice suggested that CD133+ EWS
cells had the ability to self-renew and repopulate tumors with a differentiated cell type
that comprises the bulk tumor. These findings are consistent with the current description
of cancer stem cells. These finding were further supported, in vitro, by culturing CD133+
EWS cells in sphere assay that utilizes low adherence and serum free growth conditions.
Only CD133+ cells formed spheres and they had significantly elevated levels of the stem
cell factors OCT4 and NANOG, which suggested that these cells had a stem cell-like
phenotype.
After discovering CD133+ EWS cells had bona fide cancer stem cell traits, this
finding provided a phenotype to look for other cells that were transduced with EWS-FLI1
in order to determine a cell of origin. Human pediatric mesenchymal stem cells
(hpMSCs) were the next logical cell to investigate. hpMSCs transduced with the fusion
gene and cultured as spheres underwent reprogramming with a significantly greater
induction of ESC genes compared to adult hMSCs (104). A strong induction of
glycosylated CD133 was observed in transduced hpMSCs and an even greater induction
in CD133 was reported in cells grown under sphere assay conditions as previously
performed with primary EWS cells. Transduced hpMSCs expressing CD133 were
analyzed by FACS and this revealed a small population, similar to EWS tumor cells. The
CD133+ hpMSCs also had significant upregulation in OCT4, NANOG and SOX2 as seen
previously with primary cells. Despite the permissiveness to EWS-FLI1 transduction and
the remarkable similarities between the CD133+ hpMSCs and EWS primary CD133+
cells, hpMSCs transduced with the fusion gene were unable to form tumors in mice. The
major finding in this paper revealed miR-145 to be significantly downregulated in
CD133+ EWS-FLI1 expressing hpMSCs. miR-145 has been reported to maintain a
differentiated phenotype by targeting virtually all of the known genes directly responsible
for stemness.
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Following the characterization of miR-145 in CD133+ hpMSCs expressing the
fusion gene, De Vito et al. investigated the role of this miRNA in CD133+ primary EWS
cells (80). They revealed that miR-145 was downregulated in CD133+ primary cells and
the decrease in miR-145 expression contributed heavily to CSC properties in EWS.
Moreover, TARBP2, a miRNA processing protein, was also downregulated and
determined to be responsible for a global effect on miRNA dysregulation which included
miR-145. An interesting finding in this study was that primary EWS cells grown as
spheres, compared to adherent growth conditions, displayed tumorigenic capabilities
and also had significantly decreased miR-145. This finding is particularly important
because it described a mechanism to enrich for the stem cell population in EWS which is
something that I took advantage of with EWS cell lines. Another study confirmed that
primary EWS cells grown as spheres displayed a significant increase in expression of
NANOG and OCT4 compared to adherent cells cultured with serum (112).
The cell of origin still remains elusive and it must be acknowledged that hMSC
are very likely within the lineage of the cell of origin, but no conclusive evidence supports
MSCs as the definitive cell. This is important because studies have used MSCs as a
control for comparison, which is an approach that the evidence just doesn’t support
(113). The likely cell of origin is an early mesenchymal cell derived from the
neuroectorderm that has multipotency towards both a neural crest cell and bone-derived
mesenchymal cell fate. This assertion is supported by the literature. At this point, studies
knocking down either CD99 or EZH2 in EWS cells drives differentiation towards a neural
crest stem cell or neuronal stem cell fate (114-116). This is further supported in hMSCs
and hpMSCs transduced with the fusion gene (104, 111). These transduced
mesenchymal cells displayed neural crest stem cell gene expression profiles. On the
other hand, EWS cells surviving EWS-FLI1 knockdown are driven towards a
mesenchymal differentiation path that ends with cells representing osteocyte, adipocyte
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or chondrocyte profiles (115). Studies knocking down CD99 and EWS-FLI1, separately
and together, described a stoichiometric relationship between the two molecules that
maintains a transformed oncogenic state capable of both neuronal and mesenchymal
fates (115). With the use of generating chromosomal translocations using
CRISPR/CAS9 and further investigations in cells derived from the neuroectoderm with
both MSC and neural crest stem cell lineage potential, discovering a cell of origin that
can be used to generate animal models for therapeutic studies is an attainable goal.
The role of EWS-FLI1 as the primary driver of tumor formation in EWS patients
has provided insight into developing novel therapies to treat this highly malignant
disease. Although progress is being made in developing small molecule inhibitors,
further research is needed to elucidate the mechanisms whereby the fusion protein gene
targets and protein partners initiate EWS pathogenesis. Evidence provided by Riggi et
al. demonstrating EWS-FLI1 ability to transform mouse MPC advances the research
field one step closer to developing a much needed animal model which would provide a
platform for studying EWS development and drug testing. miRNA mediated
tumorogenesis in EWS patients has led to the discovery in new prognostic markers and
therapeutic targets which could eventually have a significant impact in disease
treatment.

Tumor-Initiating Cells (TICs) Introduction
Aggressive tumors resulting from relapse and metastasis present a major
therapeutic challenge that must be addressed to successfully cure cancer patients and
until this challenge is met, patients with these advanced diseases will continue to have
poor outcomes. Strategies utilizing conventional chemotherapy and radiotherapy
currently remain ineffective when treating patients with aggressive malignancies and
mounting evidence suggests this failure is the result of standard-of-care therapies
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lacking the ability to target the heterogeneous population of tumor cells (Figure 1.3)
(112, 117, 118). Tumor-initiating cells (TICs) contribute significantly to functional
heterogeneity through a process of self-renewal leading to the preservation of a small
tumor-initiating population, and by asymmetric division resulting in non-tumor forming
daughter cells that compose the bulk of the tumor (119). This ability of TICs to maintain
their own numbers through self-renewal and ability to give rise to a differentiated rapidly
proliferating population is associated with embryonic stem cell (ESC) properties (119).
Recent studies have shown that epigenetic modifiers along with the induction of ESC
genes sustain self-renewal in TICs leading to long-term maintenance of tumors (104).
Low oxygen (hypoxic) tumor microenvironments can induce an ESC expression profile in
non-TICs representing a cellular reprogramming event into a TIC (120). Hypoxic tumor
niches exploit this cancer cell plasticity phenomenon by promoting an aggressive
phenotype by enriching for TICs (120).

Defining Stemness
TICs comprise a small subpopulation of tumor cells that have the capacity for
tumor initiation and demonstrate a phenotype similar to normal stem cells. Cells with
stem cell-like properties can be defined as cells with the ability to self-renew while giving
rise to cells that lack self-renewal potential and are unable to repopulate tumors. TICs
possess these stem-like abilities by maintaining their small population through selfrenewal and are able to give rise to a non-tumorigenic cell population that make up the
bulk of many heterogeneous tumors including EWS. Self-renewal represents a key
biological process where a TIC can preserve its population through either symmetric or
asymmetric division. Symmetric division leads to the generation of two daughter cells
that preserve the TIC phenotype, whereas, asymmetric division results in an
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Figure 1.3: General schematic of TIC model. Cancer stem cells or TICs maintain their
population through self-renewal (red arrow) and divide into differentiated non-TICS that
populate the bulk tumor. Standard chemotherapy or radiation therapy (lightening symbol)
results in therapy resistant tumor cells (purple cells) either through the selection of
therapy resistant TICs or through mutational changes in TICs that results in therapy
resistant subclones.
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undifferentiated TIC and a differentiated non-tumor-initiating daughter cell that compose
the bulk of the tumor (119).
Historically, much controversy has surrounded the terms TICs and cancer stem
cells (CSC). CSCs along with normal stem cells both have self-renewal programs,
however, the controversy lies in the uncertainty whether CSCs arise from normal stem
cells or from differentiated cells that undergo a malignant transforming event. The term
“CSC” suggests the former, but it is poorly understood if normal stem cells give rise to
CSCs. To avoid this ambiguous and controversial terminology, it has been suggested by
the field to refer to cells with stem cell programs that can initiate tumor formation as
TICs. Characterization of TICs using functional tumor-initiating cell assays have been
developed that define suspected TICs as demonstrating the following: (1) generation of
tumors in an in vivo serial xenotransplantation assay, (2) demonstration of self-renewal
using a xenograft assay by serial passaging at clonal cell doses, and (3) giving rise to
proliferative daughter cells that comprise the bulk tumor but are unable to establish
tumors by themselves (119).

Heterogeneity and the TIC Model
Intratumoral heterogeneity is suspected to be a main contributor to relapse,
metastasis and ultimately leading to therapy resistance. Mounting evidence suggests
that intratumoral heterogeneity adopts a cellular hierarchical organization placing TICs at
the apex (112, 117-119). As previously described, these cells are capable of selfrenewal and have the ability to give rise to differentiated rapidly proliferating cells that
compose the bulk tumor and are unable to form tumors. Contributing to this hierarchy
includes variations in gene expression, epigenetic differences and tumor
microenvironment (TME) influences (121). Genes that play a prominent role in selfrenewal in TICs and are crucial for maintaining pluripotency, include SOX2, OCT4 and
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NANOG (122). These embryonic stem cell factors have been demonstrated to be
significantly upregulated in TIC populations compared to the differentiated cells (104).
Recent studies have shown that epigenetic modifications including DNA methylation,
histone modification and miRNAs sustain self-renewing in TICs leading to long-term
maintenance of tumors (121). Key epigenetic repressors involved in TIC self-renewal
include the Polycomb group repressor complexes, DNA methylatransferases and miRNA
(123, 124). Hypoxic microenvironments have been shown to enrich for TICs and
maintain this stem cell phenotype through stabilized HIF-2α (120). Expression of HIF-2α
under chronic hypoxic conditions directly upregulates OCT4 by binding to its promoter
and in turn is associated with maintaining stemness (125).
The classical approach to isolating and elucidating TIC populations utilized
fluorescently activated cell sorting (FACS) for surface markers followed by serially
passaging xenografts and confirmation of repopulating the tumor similar to the parental
tumor. TIC surface markers for acute myeloid leukemia (CD34+ CD38-) (126), EWS
(CD133+) (14) and breast cancer (CD44+ CD24-) (127) revealed TIC populations that
were confirmed by an in vivo limiting dilution assay. However, in tumors that relapsed
and underwent metastasis, particularly in EWS, the CD133- population was able to form
tumors (112). This finding suggested heterogeneity within TIC populations and
moreover, supports a needed genetic and epigenetic approach to determine intratumoral
TIC populations.
Heterogeneity within the TIC subpopulations has been recently described in
metastatic renal cancer where RNAseq revealed primary tumors with genetically and
geospatially distinct subclones (128). These subclones gave rise to metastatic lesions in
the lung and liver within the same patient. This study was limited by bulk sequencing,
which fails to elucidate intratumoral diversity within TIC populations. To better
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understand lineage maps that describe the hierarchical organization and branching
evolution within tumors, sequencing at single cell resolution is required. Recently in
breast cancer, single cell-seq was used to determine the small subpopulation in primary
tumors that gives rise to metastatic cells (129). This finding elucidated the hierarchical
organization and intratumoral TIC heterogeneity in breast cancer.

Approaches to studying stemness and heterogeneity
To develop targeted therapies for TICs, studies utilizing multiple approaches to
identify and isolate TICs must be used to improve therapies in this resistant
subpopulation. Assays currently being employed to identify TICs, measure the following:
sphere-formation, in vivo growth using serial xenotransplantation, dye efflux,
chemoresistance, embryonic stem cell expression, aldehyde dehydrogenase activity
(ALDH), cell surface marker expression and more recently, single cell sequencing (129,
130).
In EWS, cells expressing the suspected TIC surface marker CD133 were isolated
from EWS tumors and demonstrated to be a viable TIC subpopulation (14). In this study
they cell sorted CD133+ cells and serially xenotranplanted these cells in NOD/SCID
mice. Using this limiting dilution approach, Suva et al. demonstrated that primary
CD133+ cells could initiate tumors and give rise to heterogeneous populations of
CD133+ TICs and differentiated CD133- daughter cells. These findings suggested that
CD133+ cells could self-renew and give rise to differentiated cells that repopulated the
bulk tumor. Moreover, in this study and others, CD133+ cells could form spheres in an in
vitro sphere assay where CD133- cells could not. Sphere assays assess the cells ability
to behave like TICs in an in vitro setting. Multiple studies measured the expression of
embryonic stem cell factors OCT4, SOX2 and NANOG in primary CD133+ cells and
CD133+ spheres (14, 104, 112). They observed, under both conditions, that CD133+
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cells expressed significantly elevated levels of OCT4 and NANOG compared to both
primary CD133- cells and cells grown under adherent conditions. Upregulation of these
stem cell genes in the CD133+ EWS cells further supports a TIC phenotype. Expression
of stem cell genes have been widely reported to be crucial for maintaining self-renewal,
pluripotency and an undifferentiated state (122).
Labs investigating chemoresistance in EWS TICs found that both primary EWS
cells and cell lines expressing high levels CD133, ALDH and dye efflux activity
demonstrated enhanced resistance to chemotherapies (112, 131). In addition to CD133
serving as a TIC marker in EWS, cells with high ALDH activity have been observed in
hematopoietic and neural stem cells (132, 133). ALDH is a detoxifying enzyme that
oxidizes intracellular aldehydes and it’s been suggested that this function plays a role in
maintaining stemness (134). Cells with high dye efflux capabilities have been described
to have elevated ATP-binding cassette transporter activity and these efflux pumps are
suggested to underlie a mechanism for drug resistance (130).
A remaining challenge to studying TICs in EWS lies in determining the
geographically separated genetic subclones that contribute the heterogeneity in EWS.
Multiple regional tumor biopsies coupled with single cell sequencing will lead to the next
major advancements in understanding the cancer. Functional screening will be needed
to confirm suspected TICs and further elucidate intratumoral TIC heterogeneity.

The Hypoxic EWS Tumor Microenvironment Introduction
Recently, importance has been placed on the role of the tumor microenvironment
(TME) in promoting tumor formation and how the interaction between cancer cells and
the TME can lead to relapse, metastasis and ultimately, therapy resistance (135, 136).
Targeting the TME in patients with aggressive malignancies is an emerging area and
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remains an opportunity to develop new therapies. EWS tumors display a diverse TME
where 85% of patients are diagnosed with malignancies primarily localized within bone,
but in 15% of patients, EWS arises within extra-osseous soft tissues (7). Moreover,
aggressive tumors develop metastatic lesions in the lungs and at distant boney sites
(137). This TME consists of tumor cells, osteoblasts, osteoclasts, immune cells,
endothelial cells, mesenchymal cells, cancer-associated fibroblasts (CAFs), etc.
Acellular components of the TME consists of extracellular matrix, various soluble factors
and extracellular vesicles that support the tumor niche . Importantly, low oxygen levels or
hypoxia is a critical feature of the TME and is associated with an aggressive phenotype
and poor prognosis in cancer patients.
Developing tumors demonstrate proliferation rates that depend significantly on an
adequate blood supply. Rapidly proliferating cells often outgrow their vascular supply
leading to periods of acute hypoxia (138). Tumor cells undergoing hypoxia adapt to
these low oxygen levels by upregulating and stabilizing hypoxia inducible factors (HIFs)
HIF -1α and -2α (138). Tumor cells undergoing a transient decrease in oxygen delivery
stabilize HIF-1α (139), which drives downstream gene expression programs involved in
shifting metabolic function from oxidative phosphorylation to glycolysis and stimulating
angiogenesis (138). This cycling pattern results in a reciprocal relationship between
proliferation rates and vessel growth that significantly contributes to the expanding
tumor. The nature of this regional fluctuation in tumor growth has been primarily
attributed to HIF -1α activity mediating the adaptive response to acute hypoxia.
However, in some contexts, HIF -2α has been demonstrated to have an overlapping and
compensatory role in the absence of HIF -1α (138). As a consequence of rapidly
proliferating tumor cells and the formation of abnormal vasculature, aggressive tumors
develop regions within the core and throughout the tumor mass that experience limited
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oxygen perfusion for extended periods of time. The initial cellular response in these
areas is mediated by HIF -1α which is maximally stabilized between 5-8 hours and then
decreases its expression as it reaches homeostasis within the hypoxic TME (138). In
addition to upregulating genes involved with angiogenesis and metabolism, HIF -1α
induces antiapoptotic gene programs to enhance survival (140). After prolonged or
chronic exposure to the hypoxic microenvironment, HIF -2α becomes stable and is
maximally expressed generally between 24 and 48 hours (139). Genes mainly
associated with an oncogenic phenotype, especially ESC programs that contribute to
generating TICs, is driven by HIF -2α, however, in some contexts, overlap exists
between HIF -1α and HIF -2α (138). These chronic hypoxic TMEs are associated with
necrotic regions and substantial evidence correlates these regions with aggressive
tumors and poor outcomes (141).
In EWS, a clinical study reported primary tumors from patients with necrosis
demonstrated a strong correlation with the worst overall survival and had an increased
chance for metastasis (142). A separate study observed significant expression of HIF 1α in 18/28 EWS patient tumors, however, no data was presented that linked patient
outcomes with HIF expression (143). Studies investigating hypoxia in EWS have mainly
focused on the role of hypoxia on metabolism, survival, anchorage-independent growth,
migration and invasion and the effects of HIF -1α on EWS-FLI (143-147). Few studies
have documented the expression of HIF-2α in hypoxic EWS cells and currently, the
temporal expression of HIF -1α and HIF -2α remains unknown.

Overview of Hypoxia and Hypoxia Inducible Factors
Hypoxia is an essential feature of the microenvironment in many solid tumors.
Tumor cells adapt to low oxygen environments by stabilizing HIFs that can induce gene
expression involved with metabolism, angiogenesis and cell survival (138). HIFs belong
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to the (P)ER-(A)RNT-(S)IM family that function as basic helix-loop-helix DNA binding
proteins (bHLH-PAS) (148-150). These transcription factors consist of oxygen sensitive
α subunit isoforms (HIF-1α, HIF-2α and HIF-3α) and a constitutively active β subunit
(HIF-1β) that forms a heterodimer (Figure 1.4) (150-152). Under normoxia (21% O2), the
HIF α subunits are constitutively transcribed and translated, however, their stability is
inhibited by hydroxylation of specific proline and arginine residues that mark the protein
for proteasomal degradation (153-155). In hypoxic conditions, the α subunits are
stabilized and translocate to the nucleus where they dimerize with HIF-1β and go on to
stimulate transcription in a DNA binding dependent manner (156, 157).
The HIF family consists of conserved protein domains throughout both the α and
β subunits. The HIFs have an N-terminal bHLH domain (required for DNA binding) and
PAS-A and PAS-B domains (required for heterodimerization). Homology between HIF1α and HIF-2α bHLH and PAS domains is roughly 85% and 70%, respectively. The high
degree of sequence similarities in these domains results in the potential for significant
overlap in DNA binding (158). Both HIF-1α and HIF-2α contain N- and C-terminal
transactivation domains (N-TAD and C-TAD) that are required for HIF target gene
activation. Within the HIF α subunits, the oxygen-dependent degradation (ODD) domain
confers oxygen dependent stabilization (153, 154, 159-161). The ODD domain contains
proline and asparagine residues that are hydroxylated during normoxic conditions (162).
HIF-3α contains the N-terminal bHLH, PAS and N-TAD domains, but lacks the C-TAD
domain. Many HIF-3α splice variants have been reported and the most common isoform,
HIF-3α4, lacks both TAD domains and functions as a negative regulator of HIF-1α. (163,
164) Target gene specificity for both α subunits is regulated by the TAD domains. Target
gene overlap between HIF-1α and HIF-2α is regulated by the C-TAD while gene
specificity is conferred by the N-TAD (165-167). Selectivity is suggested to be facilitated
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Figure 1.4: Outline of hypoxia inducible factor protein domains and most common
post-translational modifications. Post-translational modifications to protein domains
shown along with their respective enzyme and the general positive (+) or negative (-)
effects on HIF protein stability. Image is adapted from Dengler et al., 2014 Critical
Reviews in Biochemistry and Molecular Biology 49(1): 1-15. www.tandfonline.com
[tandfonline.com]
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by distinct transcriptional cofactors that recognize the N-TAD in a specific α subunit
(167).
Regulation of the HIF-1α and HIF-2α under normoxia occurs through
posttranslational modifications. In normoxic conditions, the α subunits are transcribed
and translated, however, stable expression is not maintained in the presence of higher
oxygen tension levels, resulting from their proteasomal degradation. Prolyl-4hydroxylases (PHD 1-4) hydroxylate proline residues in the ODD domain of the α
subunits (168, 169) leading to recognition of the hydroxyl groups by the von Hippel
Lindau (VHL) E3 ubiquitin ligase complex. Upon binding to VHL, the α subunits are polyubiquitinated, marking them for proteasomal degradation (153, 170, 171). PHD2 has a
stronger effect on HIF-1α while PHD3 has more of an influence on HIF-2α (169). To
catalyze the hydroxylation of the proline residues (Pro-402 and Pro-564 in HIF-1α; Pro405 and Pro-531 in HIF-2α; Pro-492 in HIF-3α), the PHDs require iron, α-ketoglutarate,
ascorbate and oxygen (155, 172). LXXLAP motifs within the ODD domains contain the
proline residues targeted by the PHD’s (163, 173). In addition to regulation of HIF
stability by the PHDs, inhibition of HIF transactivation potential is another means to
downregulate HIF function. Factor Inhibiting HIF (FIH) disrupts HIF transactivation
potential by hydroxylating asparagine (Asn-803 in HIF-1α; Asn-847 in HIF-2α) residues
within the C-TAD domains in both α subunits (174, 175). Hydroxylation in the C-TAD
domain blocks the interaction between the HIFs and co-factors involved in mediating
target gene specificity (176). Major oxygen independent regulators of HIF stability
include proteins involved with E3 ubiquitin ligase activity such as receptor of activated
protein kinase C (RACK 1), hypoxia associated factor (HAF) and carboxyl terminus of
Hsp70-interacting protein (CHIP) (177-179).
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HIF target genes contain hypoxia-response elements (HRE) with a consensus
sequence of 5’-(A/G)CGTG-3’ that are located near the proximal promoter in open
chromatin regions (180, 181). Mounting evidence suggests functional HREs require
interactions between the HIFs and other DNA-binding proteins such as FOS, CREB,
CEBPB and SP1 (181, 182). Luciferase reporter assay experiments mutating HRE and
proximal binding sites revealed a significant decrease in transcription, suggesting the
HIFs ability to induce transcription either through cooperative DNA-binding or through
recruitment of (183) HIF1α cooperatively recruit RNAPolII to HREs (184).
The most well-known HIF target genes regulate biological processes involved
with metabolism and oncogenesis (162). Extensive research has investigated the role of
HIF1α in upregulating genes central to the metabolic shift from oxidative phosphorylation
to glycolysis and regulation of oxygen supply and consumption (162). In addition to
modulating oxygen homeostasis, other HIF targets directly influence pro-oncogenic
pathways such as autophagy, cell survival, migration and invasion, stemness and
resistance to chemotherapy (181, 185, 186). Target gene selectivity between HIF-1α and
HIF-2α underlies a complex mechanism that depends on cell type, culture conditions,
hypoxia severity and duration, and the mutational landscape of HIF regulatory proteins
and miRNAs. Much attention has been focused on the severity and duration of hypoxic
exposure relative to HIF-1α and HIF-2α expression. HIF-1α is typically expressed under
acute hypoxia (6-24 hrs) in more severe hypoxic conditions (0.1-1% O2), and targets
genes involved in metabolism (PFK, LDHA, MCT4 and CA-IX)) and apoptosis (BNIP3).
Temporal expression of HIF-2α ranges from 24 hrs-days under moderate hypoxic
conditions (1-5% O2) and target genes involved in stemness (OCT4) and oncogenesis
(LOX, MMP1 and TWIST) (187). Common genes expressed by both HIFs include
VEGFA and GLUT1 (187), however, the overlap between HIF-1α and HIF-2α is
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dependent on the cellular context. Additional factors that influence HIF transactivation
specificity include the recruitment of coactivators such as CBP and p300 (151).

Hypoxia, HIFs and Cancer Stem Cells
Hypoxia is required for embryogenesis and maintenance of stem cell
pluripotency (187). In solid tumors, hypoxia is an essential feature of the
microenvironment and it is suggested that cancer stem cells (CSC) are enriched in
hypoxic regions within the tumor (188). CSCs are suspected to underly the driving force
behind tumor initiation and progression and is associated with aggressive therapy
resistant tumors (112, 189, 190). Induction of ESC genes, SOX2, OCT4 and NANOG,
consistent with CSCs have been demonstrated to be directly increased by hypoxia
(120). Furthermore, iPSC reprogramming efficiency has been enhanced by hypoxia
(191). Recently, mounting evidence suggests that the HIFs regulate the CSC
subpopulation. Both HIF-1α and HIF-2α have been shown to promote de-differentiation
through Notch signaling (192). In normal ESCs, HIF-1α has been suggested to play a
more important role, while in glioblastoma CSCs, both HIF-1α and HIF-2α were essential
for maintaining the undifferentiated state (193). Other studies have reported that HIF-2α
was exclusively expressed in CSCs and HIF-1α was stabilized under severe hypoxia in
both stem and non-stem cells (194). These findings are further supported given that
necrotic regions within tumors represent areas exposed to severe hypoxia or anoxia for
prolonged periods of time (142). In addition, tumor necrosis and HIFs are both
associated with poor patient outcomes, however, necrosis has been associated with
aggressive tumors in EWS, but it remains unknown what role the HIFs play in these
patients (143). A key gene target of HIF-2α is the ESC gene OCT4 and as a result,
functions to maintain the CSC subpopulation and promote oncogenesis (125). In
prostate cancer, SOX2 knockdown lead to decreased sphere formation. SOX2 was
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observed to be directly upregulated by both HIF-1α and HIF-2α and silencing of either
HIF resulted in a decrease in SOX2 expression. Interestingly, sphere formation in shHIF2α cells was significantly inhibited compared to shHIF-1α and control cells (120). These
findings suggest overlapping or potentially interdependent roles between HIF regulation
of stemness. In glioma, similar findings were observed where both HIF-1α and HIF-2α
knockdown cells demonstrated comparable deficits in in vitro sphere formation and in
vivo tumor formation (194). Another study in glioma revealed activation of Akt signaling
leading to enrichment of the CD133+ CSCs when cultured under hypoxia, however, HIF1α was suspected to drive this process, but this study did not account for HIF-2α (195).
Hypoxia Regulated miRNAs in Cancer
Emerging evidence suggests that miRNAs participate in mediating the hypoxic
response in normal and oncogenic cells (196). Recently, miRNAs were found to be
consistently upregulated across multiple studies in different cancer models (Table 3.1)
(197-199). These hypoxia regulated miRNAs (HRM) are differentially expressed in
hypoxic conditions under the control of HIF-1α-dependent and -independent
mechanisms (197, 200). HRMs regulated directly by HIF-1α contain hypoxia response
elements (HRE) in their promoter region and can be bound by the HIF-1 dimerized
complex (197). In addition, stabilized HIF-1α under hypoxia can elevate expression of
transcription factors that can directly increase HRM expression (201). HIF-1αindependent induction of HRMs have been shown to by regulated by signaling
cascades, such as Akt/mTOR, with elevated activity under hypoxic conditions (200).
Previous reports have demonstrated increased miRNA biogenesis under hypoxia as
result of Ago2 accumulation, however, these studies remain unclear and implicate both
HIF-1α-dependent and -independent pathways that require further investigation (202,
203).
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miR-210, the Master Hypoxia Regulated miRNA
miR-210 is considered a master HRM due to its consistent enrichment and
phenotype in normal and oncogenic cells exposed to hypoxia (204). Accumulation of
miR-210 in hypoxic cells is regulated by HIF-1α-dependent and -independent pathways
previously mentioned. The miR-210 stem-loop is located in the intronic region of the
long noncoding RNA, AK123483, on chromosome 11p15.5. MiR-210 contains a HRE in
the proximal promoter that is located 400 bp upstream of the stem-loop (205). Both HIF1α and HIF-2α bind to the HRE and activate miR-210 transcription (205, 206). Following
transcription and integration into the RISC complex, miR-210-3p functions as the guidestrand, while the miR-210-5p passenger strand is degraded by argonaute (207). In
addition, NFκB has been shown to induce miR-210 expression by binding to a
conserved κB consensus sequence in the core promoter region (208). Recently, Akt
signaling has been shown to increase miR-210 expression in a HIF-independent
manner, however, the mechanism remains unclear (209). miR-210 expression is
elevated in many solid tumors and is correlated with hypoxic tumors with poor outcomes
and moreover, makes miR-210 a suitable biomarker for prognosis (210). In hypoxic
cancer cells, miR-210 targets mRNA involved in stabilizing HIF-1α, cell cycle
progression, metabolism, DNA repair, angiogenesis, differentiation and stem cell survival
(210) .
Since miR-210 contains a HIF-1α binding site and is one of the most highly
expressed miRNA in hypoxic cells, early reports hypothesized a feedback mechanism
where miR-210 enhances HIF-1α stability and thereby increases its own expression. The
initial investigation into this potential feedback loop revealed the miR-210 mediated
silencing of glycerol-3-phosphate dehydrogenase 1-like (GPD1L) protein, an enhancer of
prolyl-hydroxylation (211). miR-210 and knocking down GPD1L confirmed the feedback

35
mechanism whereby miR-210 functions to stabilize HIF-1α under hypoxic conditions
(211).
The impact of miR-210 on cell proliferation has, at first glance, contradictory
effects in hypoxic cancer cells, however, upon deeper analysis, miR-210 mediated
affects on cell proliferation appear to be dependent on growth conditions (208, 212). As
previously discussed, hypoxic cells grown under adherent conditions in the presence of
FBS, demonstrate a decrease in their proliferative capacity. On the other hand, hypoxic
spheres form larger spheres as a result of increased proliferation compared to normoxic
spheres. Consistent with these findings, miR-210 repressed cellular proliferation in
adherent cells by targeting cell cycle regulators E2F3 (213), FGFRL1 (212) and HOXA1
(197). In hypoxic spheres, miR-210 targeted a Myc antagonist protein, MNT, resulting in
cell cycle progression (208).
A common hallmark in hypoxic cancer cell metabolism is marked by the shift in
mitochondrial respiration or oxidative phosphorylation to glycolysis (214). miR-210 has
been observed to mediate this metabolic shift in hypoxic cells by targeting enzymes
involved in oxidative phosphorylation such as ISCU1/2 (215), COX10 (216) and SDHD
(217). Interestingly, after prolonged hypoxia, miR-210 can sustain the glycolytic shift
even after the cells are returned to normoxia (218). This phenomenon has been
observed in aggressive tumors experiencing oxygen cycling.
Developing tumors undergoing transient or acute hypoxia represent an oxygen
tension cycling event that involves continuous blood vessel formation in order for the
tumor to grow. Stimulation of angiogenesis requires VEGF signaling to support the
vascular growth needs of the developing tumor. miR-210 contributes to this angiogenic
need by targeting negative regulators of the VEGF signaling pathway (218). These key
regulators include EFNA3 (218) and PTP1B (219). Given HIF-1α directly increases
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VEGF expression, stabilization of HIF-1α by miR-210 represents an indirect pathway
influencing angiogenesis. This mechanism has been observed in the angiogenic
response to ischemic renal ischemia/reperfusion injury (220).
The role of hypoxia in maintaining stem cell pluripotency and promoting
dedifferentiation is an area of ongoing research that is constantly evolving. miR-210s
role in hypoxia regulated stemness remains an emerging field of research that has
identified newly discovered mechanisms that contribute to the cancer stem cell
phenotype.

Role of miR-210 in Stemness
Under hypoxic conditions, miR-210 has been demonstrated to facilitate
dedifferentiation and support stem cell survival (221, 222). In osteosarcoma, miR-210
dedifferentiated Stro-CD117- non-osteosarcoma stem cells into Stro+CD117+
osteosarcoma stem cells (221). In this study, miR-210 increased sphere formation by
targeting, a negative regulator of Slug, NFIC resulting in increased SLUG expression
and Stro+CD117+ expression. In another osteosarcoma study, miR-210 knockdown
resulted in decreased colony formation, cell proliferation, migration and invasion, survival
and tumor formation.
In glioma stem cells, hypoxia led to increased sphere formation and was
associated with elevated miR-210 levels (223). Knockdown of miR-210 inhibited the
formation of spheres and decreased CSC markers, survival and cell cycle progression.
Underlying the hypoxic enrichment of glioma stem cells, miR-210 was demonstrated to
directly target MNT, a negative regulator of the MYC/MAX interaction. Silencing MNT
resulted in increased MYC and MAX expression which is associated with an enhanced
CSC phenotype in glioma.
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In BM-MSCs, hypoxia induced a HIF-1α mediated prosurvival program that
upregulated Akt signaling and miR-210 levels (222). Knockdown of HIF-1α resulted in
decreased survival and miR-210 expression. Further investigation revealed miR-210
targets CASP8AP2, decreasing apoptosis in hypoxic BM-MSCs. CASP8AP2 is an
integral member of the apoptotic signaling complex that activates caspase-8, facilitating
Fas-induced apoptosis (224). Currently, CASP8AP2 has been demonstrated to interact
with the caspase-8 death effector domain (224), however, CASP8AP2 has not been
extensively studied and its exact role in apoptosis remains unclear. A similar mechanism
has been outlined in HUVECS where miR-210 targets CASP8AP2, protecting HUVECs
from oxidative damage (225). In another study, miR-210 protected hypoxic
cardiomyocytes from apoptosis by targeting, the proapoptotic protein, AIFM3 (209).
Interestingly, miR-210 expression was shown to be induced by both Akt signaling and
HIF-1α. Inhibition of Akt phosphorylation in normoxic cells resulted in decreased miR210, indicating a HIF-1α independent role in miR-210 regulation. In the hypoxic
cardiomyocytes, the data indicated that miR-210 was under the dual regulation of both
Akt and HIFs (209). In EWS and other studies, Akt signaling has been shown to stabilize
and amplify HIF-1α expression but it remains unknown if miR-210 expression is directly
linked to the Akt mediated stabilization HIF-1α (226, 227).
Currently, miR-210 has been suggested as a biomarker for aggressive hypoxic
tumors, however, no link has been made between miR-210 and tumors with increased
stem cell populations. A recent study demonstrated that miR-210 contained in small
extracellular vesicles or exosomes reflected the primary tumor in mice and moreover,
these vesicles could be harvested from the peripheral vasculature as a liquid biopsy
(228). In this same study, exosomes carrying miR-210 increased angiogenesis and
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tumor formation in a xenograft mouse model. Further studies are needed to explore the
role of exosomal miR-210 on stemness.

Intercellular Signaling in the Hypoxic Tumor Microenvironment
Mounting evidence suggests that tumor cells rely on the TME for survival,
proliferation, invasion and metastasis, and maintenance of the TIC subpopulation (229,
230). Studies indicate that the TME induces phenotypic and functional differences in
tumor cells throughout the developing tumor resulting in niches with unique properties
that can contribute to resistance to cytotoxic drugs and radiotherapy (231). Hypoxia is a
key feature of the TME that is thought to underly the aggressive phenotype observed in
cancer patients. Necrotic regions in tumors often result in the worst overall outcomes in
many cancers, including EWS (142). These regions are subject to severe and prolonged
hypoxia that is associated with aggressive tumor progression (231). It has been
demonstrated that cells undergoing chronic hypoxia in these regions can communicate
with cancer cells and stroma in normoxic regions of the tumor (230). This mechanism is
suggested to underly a major contributing factor to aggressive tumors.
Recently, small extracellular vesicles (exosomes) have been described as
important mediators of cell-to-cell communications in the TME (Figure 1.5) (232, 233).
Exosomes have been shown to function as a bridge between neighboring cancer cells
and stromal cells by delivering bioactive lipids, protein, mRNAs, miRs and gDNA that
can be horizontally transferred to cells within the local TME or cells at distant sites (230).
Uptake of exosomes derived from cancer cells induces epigenetic changes in target
cells that play a significant role in tumor growth, progression, metastasis, drug
resistance, angiogenesis and induction of pre-metastatic niches (230). These
protumorigenic effects are mediated not only through cross-talk between cancer cells,
but between cancer cells and their surrounding stroma (230). More recently, Ramteke et
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Figure 1.5: Schematic diagram of hypoxic effects on EWS tumor
microenvironment (TME). Hypoxic EWS-derived exosomes (HypoxicEXO) enhance
Ewing’s sarcoma (EWS) tumor initiating-like cell (TIC) phenotype and reprogram cancerassociated fibroblasts (CAF) with enhanced tumor forming capabilities.
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al. reported that exosomes secreted from hypoxic prostate cancer cells transformed
fibroblasts into CAFs and enhanced stemness in naïve prostate cancer cells, however,
the effect that hypoxic exosomes had on inducing TIC-like cells remains unclear (234).
Interestingly, CAFs have been observed in multiple cancer models to promote tumor
growth and metastasis in the local TME and support the pre-metastatic niche at distant
sites (235). Mounting evidence suggests exosomes play a significant role in
reprogramming fibroblasts and mesenchymal stem cells into CAFs that are capable of
supporting both the local TME and at metastatic sites (236, 237). In EWS, the role of
exosomes in reprogramming cancer cells into TICs and transforming fibroblasts is
unknown. Here, we will discuss the process of exosome biogenesis and how these small
extracellular vesicles are secreted and their uptake in recipient cells. Moreover, I will
explore the function of exosomes in the hypoxic TME and the current understanding of
the role of exosomes in EWS.
Exosomes are small extracellular vesicles (40-150 nm) that originate from the
multivesicular endosome (238, 239). These vesicles are thought to arise from all cell
types and are present in all body fluids (239). The heterogeneity of exosomes is
extensive and is largely attributed to the size, phenotypic state of their derived cell and
their diverse cargo that includes proteins, RNA and DNA (240-242). Initially, exosomes
were thought to function as “cellular garbage bags” that remove excess or unwanted
cellular waste. However, this function was been supported in cancer cells that shuttle
chemotherapy drugs out of the cell and confer chemoresistance (243). Recently,
exosomes have been demonstrated to function in intercellular cross-talk in both
physiological and pathophysiological conditions in an autocrine, paracrine and endocrine
manner (244). Clinically, cancer patients have been observed to contain roughly double
the amount of circulating exosomes in their peripheral vasculature (245, 246) and the
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mechanism of action underlying the cause of enhanced exosome secretion in cancer
patients is unknown. Furthermore, liquid biopsy studies have taken advantage of this
phenomenon by isolating exosomes in these patients to uncover biomarkers that can be
used for detection, prognosis and personalized therapy approaches in cancer patients
(244).

Exosome Biogenesis
Exosome biogenesis begins with the inward budding of the plasma membrane to
form the early endosome. Invagination of the endosome results in the formation of
multivesicular bodies (MVBs) that contain the exosomes. The MVBs have two common
fates: degradation of the MVBs and their contents undergo lysosomal degradation or
fusion with the plasma membrane resulting in release of the exosomes into the
extracellular space (239). This process differentiates exosomes from other extracellular
vesicles such as apoptotic or microvesicles that emerge from evagination of the plasma
membrane. Key components involved in exosome biogenesis include the endosomal
sorting complexes required for transport complexes (ESCRT) (247, 248). Studies in the
exosome biogenesis have revealed ESCRT-dependent and -independent pathways that
appear to be context dependent. ESCRT-independent mechanism have been reported
in oligodendroglioal cells that secrete exosomes dependent on the enzymatic activity of
sphingomyelinase (249). The ESCRT machinery composes a multiprotein complex that
includes ESCRT-0, -I, -II, and -III, along with accessory proteins such as ALIX (247,
248). These proteins localize on the cytoplasmic side of the invaginating endosomes
where they recognize ubiquitinated proteins marked for sorting into the developing
exosomes (ESCRT-0,-I and -II) and facilitate membrane budding and scission (ESCRTIII), forming the individual exosomes (250). Additional proteins involved with exosome
biogenesis include TSG101, annexin A2, RAB5, RAB7 and RAB27.
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Exosome Cargo
Exosomes contain a diverse molecular cargo that affects the biogenesis
pathway, exosome secretion, targeting and uptake into target cells, and functional
alterations in the recipient cell’s phenotype (239). The exosomal payload includes lipids,
proteins, RNA and DNA (239). The lipid composition in exosomes imparts a more rigid
and durable membrane that is suggested to resist degradation during transport
throughout the body. Enrichment of cholesterol, sphingomylein, hexosylceramides,
phosphatidylserine and saturated fatty acids compose exosomal membranes (251-254).
Exosomes contain proteins that are generally considered markers for exosomes
that participate in the exosome biogenesis pathway, and proteins that reflect the cell of
origin and its physiological conditions (240. Currently, no single marker exists to
distinguish between exosomes and other extracellular vesicles, however, protein
commonly used to confer the presence of exosomes include: tetraspanins (CD9, CD63,
CD81 and CD82), MHC molecules, heat shock proteins, Alix and TSG101 {Colombo,
2014 #1245, 255-257). Exosomes are abundant in proteins that compose the plasma
membrane, cytoskeleton, cytosol and proteins involved in vesicular trafficking (250, 258,
259). Protein content can vary dramatically under different environments such as
hypoxia, and when cells undergo apoptosis resulting in apoptotic bodies (260).
The RNA profile typically observed in exosomes consists of small RNAs <700
nucleotides compared to cellular RNA profiles ranging from 400-12,000 nucleotides.
These bioactive RNAs include mRNA, lncRNA, miRNA, piwiRNA, tRNA and Y-RNA
(242, 261-263). Ribosomal RNA has been reported in exosomes but it is suggested that
the presence of rRNA is the result of microvesicle contamination (263). miRNAs are the
most widely studied RNA in exosomes due to their functional ability to silence target
mRNAs once delivered to recipient cells via exosomes . Interestingly, the Kalluri lab
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demonstrated that miRNA are bound to Argonaut forming a stable RISC in exosomes
and moreover, this discovery was the first to convincingly show miRNA biogenesis
continues within exosomes which supports previous claims of the selective sorting of
miRNAs into exosomes (264). Mounting evidence suggests that miRNA loading into
exosomes is a deliberate and selective process rather than by passive loading (264).
The selective loading of miRNA into exosomes has been demonstrated to be regulated
by the heterogeneous nuclear ribonucleoprotein (hnRNP) A2B1 (265). A2B1 belong to a
family of hnRNPs that facilitate the trafficking of RNA. A2B1 recognizes a GGAG motif in
miRNA that directs loading into exosomes (265). The selective loading of mRNA into
exosomes is suggested to occur through a similar mechanism where A2B1 recognizes a
25 nt motif containing a CTGCC sequence (266). Intact functional exosomal mRNA was
shown to be translatable in recipient cells in a study that co-culture human mast cells
with exosomes derived from mouse mast cells resulting in murine proteins expressed in
human mast cells (242). Further supporting this finding, another study GFP-tagged
mRNA and observed that exosomal delivery of this tagged mRNA expressed green
fluorescence in the exosome treated cells. Moreover, an important control in this study
reported the absence of the GFP tagged protein in the exosomes (267). Hypoxia has
been shown to induce the selective sorting of both miRNA and mRNA reflecting the RNA
expression profile observed in the hypoxic cells (232, 233).
The DNA content in exosomes is far less explored but has significant potential for
use as a biomarker in the detection of tumors and other pathophysiological conditions .
Exosomes derived from MYC amplified tumors contained the oncogene MYC dsDNA
and reflected the overall mutational landscape of the parental tumor cells. Fibroblasts
treated with these exosomes revealed the transfer of MYC DNA in the cytosol and
nucleus, however, no functional observations were made (268).
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Exosome Secretion
Once the exosomes are packaged, the MVBs migrate to and fuse with the
plasma membrane releasing the exosomes in to the extracellular space (239). The
mechanism involving the trafficking, docking and fusion of the MVBs with the plasma
membrane is not well understood and is an area of ongoing research. Proteins required
for this process include actin and myosin (cytoskeleton), myosins and kinesins
(molecular motors), and GTPases and SNAREs (targeting and fusion) (269). Rab
GTPase family members Rab11, Rab27 and Rab 35 have been demonstrated to be
involved with exosome secretion in different contexts (270-272), however, selective
knockdown of the GTPases result in partial decreases in exosome release. Proteins
implicated in MVB fusion to the plasma membrane include SNARE complex members
VAMP7 and synaptotagmin VII (273, 274). These proteins have been shown to have cell
type dependent roles in either exosome secretion or lysosomal fusion.

Exosome Interactions with Recipient Cells
Interactions between exosomes and recipient cells occur via autocrine, paracrine
and endocrine mechanisms in both physiological and pathophysiological conditions. The
ability of exosomes to deliver its cargo to target cells depends on their interactions with
recipient cells (239). The mechanism underlying the cellular specificity of exosomal
targeting remains unknown, however, studies investigating how exosomes bind to target
cells are becoming clearer. Uptake of exosomes into cells involves ligand-receptor
interactions that can trigger either receptor mediated endocytosis or signal transduction
(115), membrane fusion (252, 275) and phagocytosis (276). Ligand-receptor interactions
between exosomes and target cells include exosomal proteins MHC I/II (277) and
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tetraspanin receptors (115) capable of binding to integrins on the cell surface triggering
signaling pathways or endorcytosis.

Function of Exosomes in the Hypoxic TME
Exosomes are enriched in the TME and function in the cross-talk between cancer
cells and their surrounding stroma. In cancer, exosomes have been demonstrated to
play a significant role in invasion and migration, proliferation, angiogenesis, therapy
resistance, metabolism, immune evasion and stemness. Exosomes alter the phenotype
in recipient cells largely through the delivery of their cargo (230). Currently, exosomal
delivery of bioactive proteins and miRNA have received the greatest attention, however,
these studies are in their nascent stages. In hypoxia studies, cancer-derived exosomal
proteins play an import role in promoting cancer progression. Observations in hypoxic
nasopharyngeal carcinoma cells revealed transcriptionally active HIF-1α present within
their hypoxic derived exosomes (115). Recipient cells treated with exosomes carrying
HIF-1α demonstrated an invasive and EMT phenotype associated with decreased Ecadherin expression coupled with increased N-cadherin levels. Interestingly, HIF-1α
delivered to target cells accumulated in the recipient cell’s nucleus and maintained its
stability in these cells with functional PHDs and Von Hippel Lindau E3 ligases (260). It
was suggested that HIF-1α was protected from proteasomal degradation by an
undefined mechanism where internalization of exosomal HIF-1α mediated shuttling
directly to the nucleus (260). In prostate cancer, delivery of hypoxic derived exosomes
increased invasion, migration and stemness in normoxic prostate cancer cells, and
reprogrammed prostate fibroblasts into CAFs (234). IPA network analysis of the
proteomic profile in hypoxic exosomes indicated enrichment of proteins involved in
targeting adherens junctions. This network was suggested to underly the observations of
the hypoxic exosome mediated effects on invasion and migration, however, these
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networks were not validated and do not explain the effects associated with induction of
stemness in normoxic prostate cancer cells or reprogramming of fibroblasts into CAFs.
Proteins elevated in the hypoxic exosomes included MMP-2, MMP-9 (associated with
metastasis) and various molecules involved in cancer signaling pathways such as TGFβ2, TNF1α, IL6, Akt, ILK1 and β-catenin (234).
Increasing efforts are being made to elucidate the mechanisms underlying the
exosome mediated transfer of miRNAs to target cells and the pro-oncogenic effects that
result from this process. Recent studies in breast cancer revealed exosomal miRNA
promoted tumorigenesis in a Dicer-dependent manner and moreover, Dicer was
demonstrated to facilitate miRNA processing from pre-miRNAs to mature miRNAs in
exosomes resulting in stable miRNA capable of exerting long lasting pro-tumorigenic
effects in recipient cells (264). It is well established that the internalization of cancer
derived exosomes into recipient cells introduces a myriad of miRNA with overlapping
targets capable of interacting with the same mRNA in the host cell and eliciting similar
oncogenic effects (244, 264, 278). Currently, most studies have focused on single
miRNA and their targets, however, the authors noted that their observed effects were
modest in most cases and could be attributed to other miRNAs with overlapping mRNA
targets. Hypoxic oral squamous cell carcinoma cells were reported to secrete exosomes
with enriched miR-21 capable of promoting a metastatic phenotype in a HIF-1α and HIF2α dependent manner (233). Upon overexpression and knockdown of miR-21 using
mimics and inhibitors, the authors reported a modest effect on tumor formation,
suggesting a more complex miRNA network contributing to the hypoxic exosome effects
(233).
Cancer-associated fibroblasts participate in the TME by supporting cancer cell
invasion, proliferation and metastasis (279) CAFs overexpress α-SMA compared to
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normal fibroblasts and detection of α-SMA is generally used as a reliable CAF marker
(279). The mechanism describing how normal fibroblasts are reprogrammed into CAFs
is still unclear. However, mounting evidence suggests the CAFs arise from exosomes
secreted from cancer cells in the local TME (234) and currently, no studies in EWS have
reported an exosome mediated induction of the CAF phenotype. Exosomes secreted
from hypoxic prostate cancer cells induced expression of α-SMA in prostate fibroblasts,
suggesting that hypoxia enhances CAF reprogramming via an exosome mediated
process (234). Recently, breast cancer derived exosomes delivering miR-9 to human
breast fibroblasts was demonstrated to enhance the switch to CAFs (236). Another study
in breast cancer revealed the miRNA cargo in breast cancer derived exosomes
transformed endothelial cells with tumorigenic capabilities (264). In a previous report,
exosomes derived from colorectal cancer cells induced α-SMA expression and
anchorage-independent growth in recipient fibroblasts (280). Recently, gastric cancer
derived exosomes were shown to mediate CAF induction by increasing Akt signaling
(281) and in several other reports, activated Akt signaling was observed to underly
development and progression of malignant fibrosarcoma (282, 283).

Exosome Studies in EWS
The role of exosomes in EWS has not been extensively explored. Initial reports
focused on the mRNA profile in exosomes isolated from EWS cell lines and patient
plasma where they identified a common transcript signature that could be used as
biomarkers for detection of minimal residual disease (113). Other reports demonstrated
that shCD99 EWS-derived exosomes could transfer enriched miR-34a to recipient EWS
cells and stimulate neural differentiation (114) while in another study, EWS-derived
exosomes carrying EZH2 mRNA could be delivered intact to mesenchymal stem cells
(284).
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Summary
Hypoxia is a critical feature of tumors and is associated with poor patient
prognoses. The hypoxic TME is suggested to enrich for stem-like cancer cells and
stromal cells that are protumorigenic. However, the mechanism underlying how hypoxia
promotes an aggressive phenotype in EWS remains unclear. Exosomes are small nanosized vesicles secreted from cancer cells that function within the TME as important
intercellular communicators that induce a malignant phenotype, both locally and
throughout the developing tumor. Exosomes carry bioactive lipids, protein, mRNAs,
miRs and gDNA that can be horizontally transferred to cells within the local TME or cells
at distant sites. Uptake of the exosomal RNA cargo derived from hypoxic cancer cells
has been shown to mediate protumorigenic effects in cancer cells and reprogramming of
fibroblasts into CAFs. In EWS, the role of exosomal miRNA in reprogramming cancer
cells into stem-like cells and transforming fibroblasts is unknown.
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Hypothesis and Specific Aims
Hypothesis
I hypothesize that EWS-derived exosomes secreted under hypoxic conditions
enhance stemness in EWS cells and reprogram stromal cells of the tumor
microenvironment through miRNA delivery.
Aim 1: Determine the molecular role of hypoxia in mediating EWS-derived
exosome enhancement of EWS stem-like cells.
In this aim, my working hypothesis is that the transfer of hypoxic exosomal
miRNAs to normoxic recipient cells target mRNAs that contribute to sphere formation. In
our approach to this aim, we will knockdown HIF-1α in hypoxic EWS cells and assess
the exosomal RNA content and their impact in recipient cells using in vitro sphere
formation and in vivo tumorigenesis assays. The impact of this aim will establish a
molecular mechanism through which hypoxia can promote stemness in EWS.
Aim 2: Determine the role of hypoxic EWS-derived exosomes on Akt signaling in
EWS spheres and cancer-associated fibroblasts.
In this aim, our working hypothesis is that hypoxic EWS cells secrete exosomes
that activate Akt in EWS spheres and reprogram NIH3T3 fibroblasts into tumorigenic
CAFs. In our approach to this aim, we will analyze the RNA content in hypoxic
exosomes and determine the miRNA and mRNA that may stimulate Akt signaling in
EWS spheres and transformed CAFs. The impact of this aim will establish a novel
mechanism by which hypoxic exosomes can reprogram neighboring EWS and
microenvironment cells into tumor initiating cells.
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Chapter II
Materials and Methods
Cell culture and hypoxia exposure
EWS cell lines A673 and SK-ES-1, and the mouse embryonic fibroblast cell line
NIH3T3 were obtained from the American Type Culture Collection (ATCC, Manassas,
VA, USA). All cells were cultured in RPMI-1640 medium supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin (Invitrogen, CA, USA) as adherent
monolayers in a humidity-controlled incubator at 5% CO2 and 21% O2 at 37°C. Hypoxia
experiments for adherent cell growth and sphere formation were performed with a
Thermo Scientific™ Heracell™ VIOS CO2 trigas incubator (Thermo Fisher Scientific,
Waltham, MA, USA) at 5% CO2/95% N2 and oxygen levels maintained at 1% O2 at 37°C.
For exosome isolation, A673 and SK-ES-1 cells were cultured in RPMI-1640 media
containing 10% exosome-free FBS (System Biosciences, Palo Alto, CA, USA), 1%
glutamine and 5% penicillin/streptomycin (Gibco, Carlsbad, CA, USA). In all studies, cell
lines were maintained in culture for no more than 10 passages.

siRNA and miRNA transfection
Pre-designed HIF-1α, CASP8AP2 and Non-Targeting Control (NTC) ONTARGET plus siRNAs in SMARTpool format were obatained from Dharmacon (Horizon
Discovery, Waterbeach, UK). miR-210-3p mimics, miR-210-3p inhibitor and negative
control (miR-scramble) mimics were purchased from Ambion (Thermo Fisher Scientific,
Waltham, MA, USA). All transient transfections were performed with Lipofectamine
RNAiMAX (Invitrogen, Waltham, MA, USA) according to the manufacturer’s instructions
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Following transfections, cells were used in downstream exosome isolations, sarcosphere
assays and/or immunoblotting.

MK-2206, Akt inhibitor, treatment
A673 and SK-ES-1 cells were seeded at a density of 5 X 105 per well in 6-well
plates and allowed to adhere overnight. Following cell adherence, the EWS cells were
treated with DMSO or MK-2206 (Selleckchem, Pittsburgh, PA) [IC50] indicated in the
figure legend. The cells were cultured under normoxic or hypoxic conditions for 48 hrs in
exosome-free media. After 48 hrs, the cells were lysed for immunoblotting or PCR and
the conditioned media was processed for exosome isolation, followed by PCR or coculturing assays.

Exosome isolation
Exosomes were prepared from the cell culture supernatant of A673 and SK-ES-1
EWS cells using ultracentrifugation and filtration protocols as described previously (285).
Briefly, EWS cells cultured to 70% confluency were washed with PBS and cultured in
RPMI 1640 media containing 10% exosome-free FBS (System Biosciences, Palo Alto,
CA, USA) under normoxia (21% O2) and hypoxia (1% O2) for 48 hrs. The conditioned
media was collected and centrifuged for 10 min at 300 x g, 20 min at 2000 x g to remove
cell debris, and 30 min at 10,000 x g to remove microvessicles larger than 200 nm.
For standard ultracentrifugation, the raw exosomes were collected by
ultracentrifugation at 100,000 x g for 90 min in a SW 28 rotor (Beckman Coulter,
Chaska, MN, USA). Exosome pellets were washed with PBS and passed through a 0.2
µm SFCA filter (Thermo Fisher Scientific, Waltham, MA, USA) to remove large
contaminating lipid and vesicular aggregates.
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For exosome isolation using an OptiPrepTM (Sigma Aldrich, St. Louis, MO, USA )
solution density gradient, the raw exosomes were added to the top of discontinuous
gradient. The OptiPrepTM (iodixanol) gradients were prepared from a 60% (w/v) iodixanol
stock and diluted with 0.25 M sucrose, 10 mM Tris-HCL at a pH of 7.5 to make the
following solutions: 40%, 20%, 10% and 5% (w/v). The gradient was prepared by
layering 3 ml of each solution, beginning with 40%, to the bottom of a 10 ml Ultraclear
polypropylene tube (Beckman Coulter, Chaska, MN, USA). The prepared OptiPrepTM
solution was centrifuged at 100,000 x g for 90 min in a SW40Ti swinging bucket
(Beckman Coulter, Chaska, MN, USA). Following centrifugation, twelve 1 ml fractions
were manually collected and placed individually into polycarbonate tubes (Beckman
Coulter, Chaska, MN, USA).
For exosome isolation using a sucrose cushion, the raw exosomes were overlaid
on top of a 30% sucrose/D2O cushion and centrifuged at 100,000 x g for 90 min in a
SW28 swinging bucket (Beckman Coulter, Chaska, MN, USA).
Following the exosome isolation preparations using standard ultracentrifugation,
OptiPrepTM and sucrose cushion methods, the final solutions were ultracentrifuged at
100,000 x g for 90 min in a 70.1 Ti rotor (Beckman Coulter, Chaska, MN, USA). The
exosome pellets were resuspended in 200 µl PBS and used immediately for co-culture
assays or stored at -80⁰C.
Exosomes derived from cells transfected with HIF-1α siRNAs and NTCs were
isolated using the ExoquickTM reagent (System Biosciences, Palo Alto, CA, USA) with
modifications to the vendor instructions. Briefly, conditioned media was centrifuged for
20 min at 2000 x g and 30 min at 10,000 x g. Next, ExoquickTM was added to the
conditioned media and the remaining exosome precipitation steps were followed
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according to the manufacturer’s instructions. The exosome pellet was resuspended in
200 µl PBS and used immediately for co-culture assays or stored at -80⁰C.

Nanoparticle tracking analysis (NTA)
Exosomes were analyzed using a NanoSight NS300 (NanoSight Ltd, Navato,
CA, USA). A red laser beam was used to visualize particles and assess their movement
under Brownian motion. Illuminated particles were recorded and analyzed using the NTA
software (NTA 3.1 Build 3.1.54) which applies the two-dimensional Stokes-Einstein
equation to calculate size distribution and concentration of nano-sized particles.

Electron microscopy
Transmission electron microscopy (TEM) imaging of exosomes was performed
as previously described (286), with some modifications. Briefly, exosomes were fixed for
1 hr in a mixture of 2% paraformaldehyde, 2% glutaraldehyde in 0.1 M Sorensen’s
phosphate buffer. Following fixation, the exosome sample was layered on a
formvar/silicon monoxide–coated 200 mesh grid and air-dried for 2 min. Grids were then
stained with Nanovan negative stain (Nanoprobes, Yaphank, NY, USA) and air-dried for
an additional 2 min. Samples were observed at 80Kv with a Tecnai G2 Transmission
Electron Microscope (FEI Company, Hillsboro, OR, USA). For scanning electron
microscropy (SEM), exosome samples were fixed using the same Sorensen’s fixation
cocktail. Samples were washed three times with Sorensen’s phosphate buffer prior to
and after fixation with 1% osmium tetroxide. Next, samples were dehydrated in a graded
ethanol series (50%, 70%, 90%, 100%) three times per steps. Following dehydration,
exosome samples were kept in hexamethyldisilazane overnight to air dry and then
placed on a glass coverslip. A 50 nm layer of gold/palladium was sputter coated
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(Hummer VI Anatech, Sparks, NV) onto each sample. Samples were observed at 30Kv
with a Quanta 200 Scanning Electron Microscope (FEI Company, Hillsboro, OR).

Sarcosphere assay
A673 and SK-ES-1 parental cells and cells transfected with CASP8AP2 siRNAs,
NTCs, miR-210 mimics, miR-210 inhibitors and negative control mimics were cultured in
serum-free media in non-adherent conditions. To prevent cell aggregations resulting in
false positives, cells were seeded at low densities (20 cells/µL) in 6-well or 24-well
Corning ultra-low attachment plates in sphere media composed of DMEM/F12
supplemented with 20 ng/mL EGF, 40 ng/mL bFGF, 2 µg/mL Heparin, 0.1 mM βmercaptoethanol, 1% B27, 1% N2 and 1% penicillin/streptomycin. Sphere formation was
assessed, microscopically, in cells grown under normoxia (21% O2) and hypoxia (1% O2)
after 5 days. To assess sphere formation in EWS and NIH3T3 cells pre-treated with
exosomes, EWS cells (1000 cells/well) were cultured at a low density (1 cell/µL) in 24well low attachment plates with serum-free sphere media (as previously mentioned).
Exosomes (20 µg/mL) derived from EWS cells cultured under normoxic and hypoxic
conditions were added to A673 and SK-ES-1 cells, respectively. Sarcospheres were
counted using a microscope after 5 days. All experiments were performed in triplicate.
For siRNA experiments, exosomes derived from EWS cells transfected with
siHIF-1α or NTC were cultured with parental EWS cells and assessed for sphere
formation after 5 days.
For miRNA experiments, EWS cells transfected with miR-210 inhibitors were cocultured with hypoxic exosomes derived from their parental cell line as previously
mentioned. Sphere formation and immunoblotting was assessed after 5 days.
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Colony formation assay
NIH3T3 fibroblasts (2 X 103 cells/well) were co-cultured with SK-ES-1 NormoxicEXO and
HypoxicEXO (20µg/mL) in 0.3% agar semisolid RPMI 1640 media containing 10%
exosome-free FBS (System Biosciences, Palo Alto, CA, USA) and plated in triplicate in
12-well plates. Following 3 weeks, colony formation with > 50 cells was counted using an
inverted microscope.

Western blot
EWS cells (2 X 104 cells/well) were seeded in a 6-well ultra-low adherent plate
(Corning) and pretreated with exosomes (0 or 20 µg/mL) in a sphere assay. Following 5
days, cells were harvested and lysed for use in western blot. NIH3T3 fibroblasts (1 X106
cells/well) were plated in an adherent 6-well plate and co-cultured with SK-ES-1
NormoxicEXO and HypoxicEXO (20 µg/mL) for 24, 28 and 72 hours. Total protein was
isolated from cells and exosomes using RIPA lysis buffer (Thermo Fisher Scientific,
Waltham, MA, USA). Protein from cells was quantified using the BCA method (Pierce,
Waltham, MA, USA) and the amount of protein in exosomes was estimated by
measuring protein content with the Bradford assay (Bio-Rad, Hercules, CA, USA). SDSPAGE was conducted under reducing or non-reducing conditions followed by
immunoblot as previously described (287). Antibodies used in this experiment were Myc,
Oct 3/4, TSG101, CD63, MIC2 (CD99), FLI (EWS-FLI1), Calnexin (1:500, all Santa Cruz
Biotechnology, Dallas, TX, USA), HIF-1α (1:1000, BD Biosciences, San Jose, CA, USA),
CASP8AP2/FLASH (1:1000, Abcam, Cambrige, UK), α-SMA, phospho-AKT, AKT,
mTORC1, phosphor-mTORC1, EZH2, Sox2, Nanog, IGF-1R (1:1000, all Cell Signaling,
Danvers, MA), CD133 (1:50, Miltenyi Biotec, Waltham, MA) and α-Tubulin (1:4000,
Sigma Aldrich, St. Louis, MO, USA). Blots were incubated with appropriate horseradish
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peroxidase-tagged secondary antibodies and visualized using the MYECL Imager
(Thermo Fisher Scientific, Waltham, MA, USA).

RNA isolation, RNA-seq and analysis
EWS cell and exosome total RNA was isolated using miRCURYTM RNA Isolation
Kit according to the manufacturer’s protocol. RNA concentrations and quality were
determined by ND-1000 (Nanodrop Technologies, Wimington, DE, USA) and Fragment
Analyzer automated CE systems (Agilent, Santa Clara, CA, USA). Eletropherograms
were generated using the Fragment Analyzer. Library preparation RNA-seq and miRNAseq were performed using KAPA Stranded mRNA-Seq Kit (Roche Company) and
QIAseq miRNA Library Kit (Qiagen, Hilden , Germany), respectively. Sequencing was
performed using the Illumina HiSeq3000 system (Illumina, San Diego, CA, USA). For the
mRNA read counts, the reads were first mapped to the latest UCSC transcript set using
Bowtie2 version 2.1.0 and the gene expression level was estimated using RSEM
v1.2.15. TMM (trimmed mean of M-values) was used to normalize the gene expression.
Differentially expressed genes were identified using the edgeR package of Bioconductor.
Genes showing altered expression with p < 0.05 and more than 1.5 fold changes were
considered differentially expressed. The miRNA count was calculated using the
QIAseqmiRNA platform (http://ngsdataanalysis.sabiosciences.co-m/QIAseqmiRNA/).
The cutoff of differential miRNA was a fold-change threshold of 1.5 and maximum pvalue of 0.05. Ingenuity Pathway Analysis (IPA) software (Ingenuity® Systems,
www.ingenuity.com) was used to identify biological functional pathways and networks
associated with differentially expressed mRNAs and miRNAs. Network score presented
as –log (p value) and statistical significance (p<0.05) was performed using Fisher’s exact
test.
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Real-time quantitative PCR
For mRNA quantification, cDNA was obtained using the iScript Advanced cDNA
Kit for RT-qRCR (BIO-RAD, Hercules, CA). Typically, 2 µg of total RNA was used as
template per reaction. Real-time PCR amplification was performed using a Taqman
Gene Expression Master Mix and Taqman primers EWS-FLI1, SOX2, OCT4, NANOG
and MYC (Applied Biosystems, Waltham, MA, USA) and each target gene was
normalized to GAPDH (Applied Biosystems, Waltham, MA, USA). For miRNA
quantification, miRNA was reverse transcribed and amplified using a Taqman MicroRNA
assay kit (Applied Biosystems, Waltham, MA, USA). The Taqman probe based primers
included has-miR-145, has-miR-210 and endogenous controls RNU6B and has-miR-16
(Applied Biosystems, Waltham, MA, USA). Both mRNA and miRNA RT-qPCR
amplification was performed using the QuantSudio 3 instrument (Applied Biosystems,
Waltham, MA, USA). Relative quantification was calculated using a comparartive Ct
method.

Apoptosis Assay
To detect apoptosis in EWS spheres transfected with NTC or siCASP8AP2,
spheres were dissociated and fluorescently stained using an Annexin-V-FITC/PI flow
cytometry assay kit (BD Biosciences, San Jose, CA) according to the manufacturer’s
instructions. Quantification of apoptotic cells were performed with the FACSCalibur
system (BD Biosciences, San Jose, CA).

Tumorgenicity Assays
Four-to-six week old NOD-SCID with common gamma chain deletion (NSG) mice were
purchased from Jackson Laboratories (Bar Harbor, ME). All animal studies were
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performed under an Institutional Animal Care and Use Committee (IACUC) approved
protocol in accordance with federal, state and UNMC guidelines.
SK-ES-1 cells (1X 105) were inoculated subcutaneously into the right flank of NSG mice
(n=7/group). On the day of injection, SK-ES-1 cells were suspended in a 2:1 mixture
(PBS:Matrigel) (BD Biosciences, San Jose, CA, USA) and with either (i) PBS (control),
(ii) NormoxicEXO or (iii) HypoxicEXO (20µg/mL). Mice were injected intratumorally with
PBS, NormoxicEXO or HypoxicEXO (20µg/mL) twice per week for six weeks.
NIH3T3 cells (1X 105 cells/well) were pretreated with NormoxicEXO and HypoxicEXO
(20µg/mL) for 72 hrs. Following incubation period, NIH3T3 cells were harvested and 1X
105 cells were mixed respectively with PBS, NormoxicEXO and HypoxicEXO (20 µg) in 150
µL PBS and then injected into the right flank of NSG mice (n=5/group).
Tumor formation was measured three times a week using the Biopticon TumorImager
(Princeton, NJ). When the tumor volume reached the end of their time course or 1 cm3,
the experiment was concluded and mice were euthanized using CO2 and cervical
dislocation. Tumors were removed and processed for either FACS analysis, western
blot, H&E staining or immunohistochemistry. Briefly, IHC staining was performed using
α-SMA antibody (1:1000, Cell Signaling, Danvers, MA) and ImageJ was used to quantify
staining density.

Tumor dissociation and FACS analysis
After removal of SK-ES-1 tumors treated with either PBS, NormoxicEXO or HypoxicEXO,
tumor samples were mechanically dissociated and enzymatically digested with
collagenase II (56 mg/L) and IV (170 mg/L) (Sigma, St. Louis, MO, USA) in a shaking
incubator for 45 min at 37 °C. Sample were pipetted vigorously and passed through a 70
µM nylon cell strainer (Miltenyi Biotec, Waltham, MA). Erythrolysis was carried out using
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1X RBC lysis buffer (Miltenyi Biotec, Waltham, MA) according to manufacturer’s
instructions. Viability was assessed in disaggregated single cells using trypan blue
staining. Samples with ~90% viability were analyzed by fluorescence-activated cell
sorting (FACS) using CD133/1 phycoerythrin (AC133), 1/10) antibody (Miltenyi Biotec,
Waltham, MA), isotype control mouse IgG1 phycoerythrin (1/10, BD Pharmingen, San
Jose, CA, USA) and LIVE/DEAD (Invitrogen, Waltham, MA, USA) viability stain in a
LSRII apparatus (BD Biosciences, San Jose, CA, USA).

Statistical analysis
Statistical analysis between groups were calculated using Student t test or oneway ANOVA with Tukey’s multiple comparisons test. A value of p< 0.05 was considered
statistically significant. All data is presented as mean + standard error of the mean
(SEM). ΔΔCq method was used to calculate relative gene expression from qRT-PCR
data. All experiments were replicated a minimum of three times unless otherwise
indicated.
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Chapter III
Characterization of EWS NormoxicEXO and HypoxicEXO
Introduction
Small extracellular vesicles (exosomes) have been described as important
mediators of cell-to-cell communicators in the TME (230). Exosomes arise from the early
endosome and are trafficked through the cell within multivesicular bodies (MVBs). MVBs
fuse with the plasma membrane releasing these exosomes into the extracellular space.
These small vesicles range in size from 30-150 nm and carry bioactive lipids, protein,
mRNAs, miRs and gDNA that can be horizontally transferred to cells within the local
TME or cells at distant sites (239). Exosomes enter the peripheral vasculature to reach
distant target cells and given this ability, cancer-derived exosomes may serve as a novel
diagnostic and prognostic marker that can be assessed through liquid biopsy (244).
The role of exosomes in EWS is currently unclear. Initially, exosomes isolated
from EWS cell lines and patient serum identified mRNA (113) and miRNA (115) profiles.
These reports investigated the functional (115) and biomarker (113) significance of EWS
exosomes. Studies in other cancer models investigating the role of hypoxic exosomes
have provided insight into how hypoxic tumors can secrete exosomes that propagate an
aggressive phenotype in cells outside the hypoxic niche (233). Exosomes released from
hypoxic prostate cancer cells enhanced sphere formation in normoxic cells and induced
a cancer-associated fibroblasts (CAF) phenotype in normal prostate fibroblasts (234),
but they were unable to elucidate a mechanism describing how hypoxic exosomes
promoted stemness in normoxic cells and reprogrammed CAFs. CAFs have been
observed in multiple cancer models to promote tumor growth and metastasis in the local
TME and support the pre-metastatic niche at distant sites (279).
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The role of exosomes in promoting stemness and induction of the CAF
phenotype in EWS is unknown and highlights a major gap in scientific knowledge. In
this study, we sought to characterize the protein, mRNA and miRNA content in EWS
exosomes, furthermore, we performed RNA-seq followed by IPA analysis in order to
identify miRNAs and mRNAs that may play a role in promoting sphere formation in EWS
cells and reprogramming fibroblasts into CAFs.

Results
To determine an optimal exosome isolation method for downstream functional
assays, we cultured SK-ES-1 cells in exosome-free media for 48 hours and processed
the conditioned media using the following methods: Opti-Prep gradient, discontinuous
sucrose gradient and ultracentrifugation followed by microfiltration (Figure 3.1). All of the
methods isolated particles within the acceptable size range for exosomes. The sucrose
isolation method yielded the smallest average exosome size (117.8 nm) while the OptiPrep and ultracentrifugation methods resulted in much bigger particle sizes (152.6 nm
and 142.6 nm, respectively). As expected however, the ultracentrifugation technique
yielded a significantly greater particle concentration compared to the other isolation
methods. Together, these results indicate that the ultracentrifugation exosome isolation
method is an acceptable isolation method and will yield adequate exosomes for
downstream functional assays.
To investigate the role of hypoxia on exosome secretion in EWS, A673 and SKES-1 cells, we first measured the expression of HIF-1α in A673 and SK-ES-1 EWS cells
cultured under 1% O2 for an increasing duration (310). In both EWS cell lines, HIF -1α
expression stabilized at 6 hrs (Figure 3.2A). Since HIF-1α expression was stable at 48
hours and exosome isolations typically require 48 hour incubations in exosome-depleted
media, we proceeded to culture our EWS cells in exosome-free media under normoxic
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(21%O2) and hypoxic (1%O2) conditions for 48 hours. EWS-derived exosomes were
isolated by collecting the supernatant and performing multiple centrifugation and
ultracentrifugation steps, followed by microfiltration. The exosomes were analyzed using
Nanosight tracking analysis (NTA) to measure particle size and concentration. NTA
revealed both A673 and SK-ES-1 exosomes with particle sizes within the expected size
range of 30-150 nm (Figure 3.2B) (310). In both cell lines, the total particle concentration
of hypoxic EWS-derived exosomes (HypoxicEXO) secreted was lower than normoxic
EWS-derived exosomes (NormoxicEXO) following normalization to cell numbers.
Proliferation rates in hypoxic EWS cells were decreased ~30% compared to normoxic
cells which was consistent with the differences observed in particle concentration
between normoxic and hypoxic cells (310). Total exosomal protein was also similar to
total particle concentration and together, our findings suggest that EWS exosome
secretion is dependent on proliferation rates which is consistent with the effects of
hypoxia on cell proliferation (310).
EWS NormoxicEXO and HypoxicEXO were visualized using transmission and
scanning electron microscopy. TEM confirmed small vesicles ranging from 30-150 nm
(Figure 3.2C) (310) while SEM revealed aggregates of vesicles larger than 150 nm
(Figure 3.2D). These observations may explain the NTA results detecting particles
outside the range of exosomes. We confirmed the presence of EWS-derived exosomes
by immunoblotting for protein markers involved in exosome biogenesis. Western blotting
demonstrated decreased levels of CD63 and TSG101 in SK-ES-1 HypoxicEXO compared
to NormoxicEXO. The endoplasmic reticulum protein calnexin served as a negative control
and was not observed in either exosome lysates (Figure 3.2E) (310). Next, we probed
for proteins crucial in EWS pathogenesis. We identified CD133, EZH2, IGF-1R, EWSFLI1 and CD99 in both SK-ES-1 exosomes. Interestingly, SK-ES-1 HypoxicEXO had
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increased levels of the fusion protein EWS-FLI1 and EWS proteins, CD99 and EZH2,
which are involved in maintaining a transformed phenotype (Figure 3.3B).Total protein
isolated from NormoxicEXO and HypoxicEXO lysates was reflected in similar levels of αtubulin. Previously, EWS-FLI1 mRNA was detected in EWS exosomes, we wanted to
see if hypoxia modulated EWS-FLI1 mRNA in HypoxicEXO. Interestingly, EWS-FLI1
levels were significantly elevated in HypoxicEXO (Figure 3.3A). Together, we concluded
that our isolation method reliably captured vesicles consistent with exosome
characteristics and contained proteins and mRNA important in EWS pathogenesis.
Recently, hypoxia was demonstrated to alter mRNA and miRNA profiles in
cancer-derived exosomes. Furthermore, exosomes have been shown to genetically and
metabolically reprogram cancer cells through the delivery of their RNA payload (233).
We sought to identify mRNAs and miRNAs in our HypoxicEXO that may play a role in
promoting stemness. First, total RNA was isolated from normoxic and hypoxic SK-ES-1
cells and their derived exosomes. Capillary electrophoresis revealed a broad
composition of RNA with enrichment of small RNAs in the exosomes compared to their
respective cells (Figure 3.4) (310). Cellular RNA profiles demonstrated typical ribosomal
subunit peaks (28S and 18S), but were not seen in the exosomal lysates (288). The
presence of these ribosomal RNAs have been reported in both microvesicles and
apoptotic bodies which further supports the high quality of the exosome isolation (310).
RNAseq was performed using the Illumina HiSeq3000 to identify exosomal
miRNAs. Unsupervised hierarchical clustering identified miRNA clusters that were
significantly different between normoxic and hypoxic cells, and NormoxicEXO and
HypoxicEXO (Figures 3.5A,B) (310). We observed 467 miRNAs to be differentially
expressed between normoxic and hypoxic cells threshold for comparison of 1.5 fold with
a significance of P < 0.05) (Figure 3.5C ) (310). Hypoxic cells displayed 94 increased
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and 373 decreased miRNAs compared to normoxic cells. In HypoxicEXO, we observed 75
enriched and 90 depleted miRNAs compared to NormoxicEXO (Figure 3.5D) (310). In
Table 3.1, miRNA that are positively and negatively regulated by the HIFs are listed in
their respective columns. We plugged-in our miRNA values based on differential miRNA
expression between HypoxicEXO and NormoxicEXO. Our results were consistent with
previous studies characterizing up- and downregulated miRNAs in HypoxicEXO. Using
real-time PCR, we validated the top regulated miRNA observed in both the cellular and
exosomal miRNA-seq results and found miR-210 expression to be consistently elevated
in HypoxicEXO compared to NormoxicEXO for both EWS cell lines (Figure 3.6) (310). This
data identifies a hypoxically regulated exosomal miRNA, miR-210, that may influence
cellular function in normoxic EWS target cells and could potentially serve as a reliable
prognostic marker for hypoxic EWS tumors.
Next, we used Ingenuity Pathway Analysis (IPA) software to determine the top
experimentally verified diseases and biological functions related to these 165 miRNAs
and their predicted cellular target mRNAs. The top three categories included
“Organismal Injury and Abdormalities, Reproductive System Disease and Cancer”
(Figure 3.7A). IPA network analysis of these differentially expressed miRNAs allowed us
to gain insight into particular miRNA-mRNA interactions and narrow the predicted
biological effects that these exosome-derived miRNAs have within target cells. The top
network identified miRNAs targeting mRNA nodes involved in “Cancer Biology”
(score=23) centering on indirect interactions between significantly expressed oncogenic
miRNAs and hyperactivation of Akt signaling (Figure 3.7B). These experimentally
validated miRNAs involved in modulating Akt activity include miR-19b-3p, miR-92a-3p,
miR-25, miR-181-5p, miR-27a-3p, miR-29b-3p and miR-30c-5p. Interestingly, many of
these miRNAs (miR-9-5p, miR-27a-3p, miR-210-3p, miR-181a-5p and miR-25) are
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involved in maintaining stemness in cancer cells, however, these functions are
independent from the interactome converging on Akt signaing. Together, IPA analysis of
the miRNA cargo in HypoxicEXO identifies key miRNAs that converge on a common
pathway that has been previously demonstrated to drive a stem-like phenotype in cancer
cells.
Unsupervised hierarchical clustering identified miRNA clusters that were
significantly different between normoxic cells and NormoxicEXO, and hypoxic cells and
HypoxicEXO (Figures 3.8A,B). We observed 1,139 miRNAs to be differentially expressed
between normoxic cells and NormoxicEXO and 1052 differentially expressed miRNAs
between hypoxic cells and HypoxicEXO, threshold for comparison of 1.5 fold with a
significance of P < 0.05) (Figure 3.8C,D). NormoxicEXO displayed 640 increased and 449
decreased miRNAs compared to normoxic cells (Figure 3.8C). In HypoxicEXO, we
observed 496 enriched and 556 depleted miRNAs compared to hypoxic cells (Figure
3.8D).
Cluster analysis identified mRNAs that were significantly different between
NormoxicEXO and HypoxicEXO (Figures 3.9A). We observed 586 mRNAs to be
differentially expressed, at threshold for comparison of 1.5 fold with a significance of P <
0.05) (Figure 3.9B). In HypoxicEXO, we observed 292 enriched and 294 depleted miRNAs
compared to NormoxicEXO. IPA analysis was used to determine the top experimentally
verified diseases and biological functions related to these 586 mRNAs and their
predicted pathways. The top three categories included “Cancer, Organismal Injury and
Abnormalities, and Gastrointestinal Disease” (Figure 3.9C). IPA network analysis of
these differentially expressed mRNAs revealed predicted biological pathways that these
exosome-derived mRNAs have within target cells. The top network identified mRNAs
targeting mRNA nodes involved in “Post-Translational Modification, Hereditary Disorder,
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Neurological Disease” (score=54) converging on direct interactions between significantly
expressed mRNAs and activation of Akt signaling (Figure 3.9D).
Cluster analysis between normoxic cells and NormoxicEXO, and hypoxic cells and
HypoxicEXO revealed 11,374 and 11,729 mRNAs to be differentially expressed,
respectively (threshold for comparison of 1.5 fold with a significance of P < 0.05) (Figure
3.10A,B). NormoxicEXO displayed 4,810 increased and 6,564 decreased mRNAs
compared to normoxic cells (Figure 3.10C). In HypoxicEXO, we observed 5,038 enriched
and 6,691 depleted mRNAs compared to hypoxic cells (Figure 3.10D). mRNA-seq
revealed elevated levels of the ESC genes in exosomes compared to their respective
parental cells. Validation of the ESC mRNA using qRT-PCR demonstrated significantly
increased expression of SOX2, OCT4 and NANOG in exosomes compared to their
derived cells, respectively, (Figure 3.11A,B), however, MYC was enriched in,
NormoxicEXO and significantly depleted in HypoxicEXO when compared to their respective
cells. Interestingly, MYC was significantly increased in NormoxicEXO when compared to
HypoxicEXO, but no significant difference was observed in SOX2, OCT4 and NANOG
expression between normoxic and hypoxic exosomes.
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Figure 3.1: NanoSight tracking analysis (NTA) of SK-ES-1 exosomes isolated
using different methods. NTA of Opti-Prep, discontinuous sucrose, ultracentrifugation
methods showing particle size and relative concentration.
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Figure 3.2: Characterization of EWS Exosomes. (A) Western blot of HIF-1α in A673
and SK-ES- cells cultured under hypoxia (time points: 0, 6, 24, 48 and 72 hrs.). (B)
NanoSight tracking analysis (NTA) of normoxic and hypoxic A673 and SK-ES-1
exosomes showing particle size and relative concentration. (C) Transmission electron
micrograph (TEM) of normoxic and hypoxic A673 and SK-ES-1 exosomes. (D) Scanning
electron micrograph (SEM) of normoxic and hypoxic SK-ES-1 exosomes (magnification,
X30,000; scale bar, 1 µ). (E) Western blot of key EWS proteins EWS-FLI1, CD99,
CD133, EZH2 and IGF1R involved in EWS pathogenesis. Loading controls and
exosomes markers α-Tubulin and TSG101 were assessed respectively.
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Figure 3.3: Characterization of EWS-FLI1 in EWS exosomes. (A) Assessment of
EWS-FLI1 mRNA in SK-ES-1 NormoxicEXO and HypoxicEXO using qRT-PCR (Mean +
SEM, n=3 *, P<0.005, **, P<0.0005). RNU6B was used as a control to normalize
expression. (B) Western blot of key EWS proteins CD133, EZH2, IGF-1R, EWS-FLI1,
CD99 involved in EWS pathogenesis. Loading controls and exosomes markers αTubulin and TSG101 were assessed respectively.
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Figure 3.4: Representative electropherogram profile of total RNA in normoxic and
hypoxic SK-ES-1 cells and exosomes. Ribosomal subunits 28S and 18S were
observed in cellular RNA profiles and were absent in exosomal RNA.
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Figure 3.5: Differential expression of miRNAs in normoxic and hypoxic cells and
exosomes. Unsupervised cluster analysis of SK-ES-1 miRNAs in (A) normoxic and
hypoxic cells and (A) NormoxicEXO and HypoxicEXO . Each column represents a biological
replicate and every row denotes an individual miRNA. The Z-score color scale indicates
high expression represented by red ranging to low expression denoted by green.
Volcano plot of miRNA differentially expressed ( >1.5 fold threshold) in SK-ES-1 (C)
normoxic compared to hypoxic cells and (D) HypoxicEXO compared to NormoxicEXO.
Significance (-log10 p-value) was plotted versus fold change (log2 fold change) along
the y and x axis, respectively.
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Table 3.1: Hypoxia regulated miRNAs differentially expressed in SK-ES-1
HypoxicEXO compared to NormoxicEXO. Fold change was calculated using miRNA-seq
read counts.
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Figure 3.6: miR-210 expression in EWS exosomes. Validation of hypoxia regulated
miRNAs miR-210 A673 and SK-ES-1 NormoxicEXO and HypoxicEXO using qRT-PCR
(Mean + SEM, n=3, *, P<0.05). miR-16 was used as a control to normalize miRNA
expression.
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Figure 3.7: IPA analysis and interactome of exosomal miRs. (A) IPA analysis of the
top 15 significantly represented diseases and biological function categories for miRNA
differentially ( >1.5 fold) expressed in HypoxicEXO compared to NormoxicEXO . (B) Top
network generated by IPA software indicating differentially expressed HypoxicEXO
derived miRNAs and their predicted targets. Direct interactions are denoted by solid
lines and indirect interactions are represented by dotted lines. Red and green indicates
high and low miRNA expression, respectively.
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Figure 3.8: Differential expression of miRNAs in normoxic and hypoxic cells and
exosomes. Heatmap of differentially expressed miRNAs in SK-ES-1 (A) NormoxicEXO
compared to Normoxic cells and (B) HypoxicEXO compared to Hypoxic cells. Each column
represents a biological replicate and every row denotes an individual miRNA. The Zscore color scale indicates high expression represented by red ranging to low
expression denoted by green. Volcano plot of miRNA significantly upregulated or
downregulated ( >1.5 fold threshold) in SK-ES-1 (C) NormoxicEXO compared to Normoxic
cells and (D) HypoxicEXO compared to Hypoxic cells. Significance (-log10 p-value) was
plotted versus fold change (log2 fold change) along the y and x axis, respectively.
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Figure 3.9: Differential expression and IPA analysis of mRNAs in normoxic and
hypoxic cells and exosomes. (A) Cluster analysis of mRNAs in SK-ES-1 NormoxicEXO
and HypoxicEXO . Each column represents a biological replicate and every row denotes
an individual mRNA. The Z-score color scale indicates high expression represented by
red ranging to low expression denoted by blue. (B) Volcano plot of top differentially
expressed ( >1.5 fold threshold) mRNA significantly upregulated or downregulated in
SK-ES-1 HypoxicEXO compared to NormoxicEXO. Significance (-log10 p-value) was plotted
versus fold change (log2 fold change) along the y and x axis, respectively. (C) IPA
analysis of the top 15 significantly represented diseases and biological function
categories for mRNA differentially ( >1.5 fold) expressed in HypoxicEXO compared to
NormoxicEXO . (D) Top network generated by IPA software indicating differentially
expressed HypoxicEXO derived mRNAs and their predicted targets. Direct interactions
are denoted by solid lines and indirect interactions are represented by dotted lines. Red
and green indicates high and low mRNA expression, respectively.
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Figure 3.10: Differential expression of mRNAs in normoxic and hypoxic cells and
exosomes. Heatmap of differentially expressed mRNAs in SK-ES-1 (A) NormoxicEXO
compared to Normoxic cells and (B) HypoxicEXO compared to Hypoxic cells. Each column
represents a biological replicate and every row denotes an individual mRNA. The Zscore color scale indicates high expression represented by red ranging to low
expression denoted by green. Volcano plot of mRNA significantly upregulated or
downregulated ( >1.5 fold threshold) in SK-ES-1 (C) NormoxicEXO compared to Normoxic
cells and (D) HypoxicEXO compared to Hypoxic cells. Significance (-log10 p-value) was
plotted versus fold change (log2 fold change) along the y and x axis, respectively.
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Figure 3.11: ESC gene expression in normoxic and hypoxic EWS cells.

Differential expression of ESC genes SOX2, OCT4, NANOG and MYC in (A)
NormoxicEXO compared to Normoxic cells, (B) HypoxicEXO compared to Hypoxic
cells and (C) NormoxicEXO compared to HypoxicEXO assessed by qRT-PCR.
GAPDH was used as the endogenous control (Mean + SEM, n=3 *, P<0.05, **).
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Discussion
The major challenge facing exosome research is the ability to differentiate
between exosomes and other extracellular vesicles such as microvesicles. The methods
to discriminate between exosomes (~40-150 nm) and microvesicles (~100-1000 nm)
assess size, morphology, protein content, and buoyant density, however, these
parameters remain insufficient (285). Until the mechanisms involved in exosome
biogenesis and the selective packaging of exosomal cargo can be elucidated, current
techniques remain insufficient to fully characterize exosomes and their functional affects.
Presently, the guidelines for characterizing exosomes are based on the previously
mentioned parameters, but consideration of the pitfalls is promoted when drawing
conclusions from exosome studies (289).
The persistent difficulties in exosome studies arise from the challenges in
exosome preparations that are unable to strictly enrich for exosomes. The predominant
methods utilized in the field include exosome isolation kits, ultracentrifugation with
microfiltration, and ultracentrifugation approaches implementing Opti-Prep (iodixanol) or
sucrose gradients to isolate particles based on their buoyant density, however, each
method is associated with its own advantages and disadvantages (289). Our findings
indicated that the sucrose gradient method produced particles with the smallest average
size compared to the standard ultracentrifugation and Opti-Prep isolation methods. The
standard ultracentrifugation approach yielded significantly more particles than the other
methods and were within the acceptable size range for exosomes. Interestingly, the
Opti-Prep approach, often considered the gold standard method, yielded the greatest
particle size but produced the lowest concentration compared to the other isolation
techniques. The Opti-Prep method dilutes iodixanol into a sucrose solution. Both OptiPrep and sucrose isolations were setup as discontinuous gradients creating density
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barriers. Opti-Prep gradient solutions are iso-osmotic and prevent the rupturing of
vesicles, unlike sucrose solutions that are hyper-osmotic. Since both solutions contain
sucrose, this can often result in the aggregation of particles due to the “sticky” nature of
the hydroxyl groups on the sucrose molecules. This can cause aggregated particles to
form pellets at the bottom of tubes and therefore, defeat the purpose of the gradient.
Sucrose is also suspected of inhibiting uptake of exosome into recipient cells. Together
this would explain the low yield in both approaches using density gradient solutions and
thereby, provided us with the rationale to utilize the standard ultracentrifugation and
microfiltration method for downstream analysis and functional studies. SEM analysis of
our particles isolated using standard ultracentrifugation confirmed that aggregation of
exosome-like particles was occurring and immunoblotting of proteins involved in the
exosome biogenesis pathways further supports the standard isolation protocol as a
reliable preparation method for exosomes.
Initial studies suggested that HypoxicEXO were being secreted at an elevated rate
compared to normoxic cells (290). Our findings and others (234) indicate that exocytosis
of exosomes is dependent on cellular proliferation. A likely explanation for these
discrepancies could be attributed to the use of exosome isolation methods that utilize
polyethylene glycol to pulldown exosomes during the centrifugation process. This
approach wouldn’t be able to discriminate exosomes from microvesicles or apoptotic
bodies, and isolations significantly contaminated with these vesicles would explain the
differences in hypoxia mediated exosome secretion. No isolation approach can totally
eliminate microvesicles or apoptotic bodies, however, our method utilizes multiple
ultracentrifugation and microfiltration steps which have been overwhelming described as
a superior method. Furthermore, RNA analysis in our exosomes failed to reveal
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ribosomal peaks which are commonly observed in microvesicles and apoptotic bodies. It
also is very plausible that these differences are merely context dependent observations.
Detection of increased protein levels of EWS-FLI1, EZH2 and CD99 in
HypoxicEXO provides insight into a potential mechanism responsible for the enhanced
effects observed in cells treated with HypoxicEXO . However, in addition to elevated levels
of EWS-FLI1, EZH2 and CD99, HypoxicEXO had relatively equal levels of CD133 and
IGF-1R compared to NormoxicEXO. Studies transducing the EWS-FLI1 fusion gene into
mesenchymal stem cells, the hypothesized cell of origin, were able to elicit a similar
phenotype observed in primary EWS TICs but were unable to demonstrate tumor
formation in mice with these transformed cells (15, 49, 104, 111). This suggested that
EWS-FLI1 alone is unable to recapitulate the EWS phenotype. In separate contexts,
both CD99 and EZH2 had demonstratable roles in maintaining stemness in EWS and
together, forced expression of these proteins may reveal the necessary conditions
underlying EWS tumorigenesis (111, 115, 116). Further studies are needed to determine
the role of these proteins in EWS cells and the potential exosome mediated effect on
EWS TICs and CAF formation.
In cancer patients, exosomes are reportedly elevated within the systemic
vasculature compared to normal healthy control patients and carry biomarkers with the
potential to detect and monitor the development of tumors (244). Characterization of
mRNA in EWS cells and their derived exosomes was previously performed in order to
identify an RNA profile that could be used to detect minimal residual disease following
therapy (113). We advanced this approach by reporting differential expression of
mRNAs and miRNAs in hypoxic and normoxic EWS exosomes and in addition, we
compared RNA expression profiles between normoxic and hypoxic cells, and between
cells and their respective exosomes. Importantly, the differential expression of our
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exosomal miRNA cargo revealed selective sorting of small RNAs in HypoxicEXO that in
part reflected the miRNA profile in our hypoxic cells, that could be used to assess
prognosis in EWS patients with hypoxic tumors.
Detection of hypoxia regulated miRNAs in circulating exosomes have played a
major role as prognostic and predictive markers that correlate with metastasis and
chemoresistance (290, 291). We validated the top miRNA, miR-210, that was
differentially expressed in our hypoxic cells and HypoxicEXO. Futhermore, we identified a
miRNA profile consistent with findings in exosomes derived from hypoxic breast cancer
cells and patient samples (290, 292). Moreover, breast cancer patients with elevated
exosomal miR-210 were associated with tumor metastasis (293). In EWS patients,
EWS-FLI1 is the sole diagnostic marker that distinguishes EWS from other sarcomas
and bone cancers (8). In our study, we are the first to show a miRNA profile in EWS
exosomes that could serve as biomarkers and assist in the prediction of outcomes in
EWS patients with aggressive hypoxic tumors (310).
The effects of exosome mediated transfer of miRNAs to target cells has garnered
the most attention in the exosome field (244). Internalization of cancer derived
exosomes into recipient cells introduces a myriad of miRNAs with overlapping targets
capable of interacting with the same mRNA in the host cell and eliciting similar
oncogenic effects. Most studies have focused on the function of a singular miRNA and
the effects it has on an individual mRNA, while few studies have taken an integrated
approach to profiling the broad miRNA expression in exosomes by utilizing software to
analyze cancer pathways and networks describing predicted interactions between
miRNA and their validated targets. This approach would take into consideration the large
amount of miRNAs in exosomes and their potential overlapping targets that contribute to
a known phenotype. Analysis of our miRNA cargo revealed 75 enriched and 90 depleted
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miRNAs in HypoxicEXO compared to NormoxicEXO (310). IPA analysis of these
differentially expressed miRNAs revealed enrichment of HypoxicEXO miRNAs with
experimentally observed and predicted diseases and biological functions within the
categories of Organismal Injury and Abnormalities, Reproductive System Disease and
Cancer. The top network displayed protein targets associated with aggressive EWS
tumors and maintenance of stemness under hypoxic conditions. Analysis of this
interactome depicts Akt as the most significantly targeted protein node and notably, 7
miRNAs were revealed to interact with Akt signaling pathway. These candidate miRNAs
have been previously reported to indirectly activate Akt by silencing repressors of this
signaling pathway. In addition, IPA analysis of the mRNA in HypoxicEXO converged on
the Akt signaling pathway. These findings suggest a broader regulatory network which
may affect Akt signaling in cells treated with EWS HypoxicEXO.
Future work validating and matching the molecular profiles between exosomes
and their parental EWS tumors is needed in order to identify EWS patients with hypoxic
tumors and to devise new approaches that can overcome therapy resistant tumors.
Based on our findings, the subsequent chapters will focus on the HypoxicEXO mediated
effect on stemness by delivering exosomal miR-210 to recipient EWS cells and the
effects of exosomal miRNA on reprogramming fibroblasts into CAFs with enhanced
tumorigenicity by targeting the Akt signaling pathway.
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Chapter IV
Exosomes Secreted under Hypoxia Enhance Stemness
and Tumorigenicity in EWS.
Introduction
Hypoxia is an essential feature of the tumor microenvironment (TME) in many
solid tumors and it is suggested that enrichment of stem-like cells occurs within the
hypoxic niche (120, 294), however, this mechanism remains poorly understood in EWS.
Stabilization and activation of the hypoxia inducible factor HIF -1α in hypoxic tumor cells
plays a major role in mediating the adaptive response to low oxygen levels (140). HIF 1α has been demonstrated to regulate tumor formation and stem cell survival in hypoxic
cancer cells by inhibiting apoptosis (194). Emerging evidence indicates intercellular
communication between tumor cells in hypoxic and normoxic regions contributes to
functional differences associated with hypoxic tumors (233, 234, 295).
Recently, small extracellular vesicles called exosomes have been described as
important mediators of cell-to-cell communication that transduce signals to neighboring
cells and cells outside the local TME (233). This function may provide a mechanism for
how hypoxic cells communicate beyond their hypoxic niche and promote aggressive
tumors. In the TME, exosomes range in size from 30-150 nm and carry bioactive lipids,
protein, mRNAs, miRNAs and gDNA that can be horizontally transferred to cancer cells
that drive tumor growth, progression, metastasis, drug resistance, angiogenesis and
induction of pre-metastatic niches (244).
The role of hypoxic exosomes have provided insight into how hypoxic tumors can
secrete exosomes that propagate an aggressive phenotype in cells outside the hypoxic
niche. Exosomes released from hypoxic prostate cancer cells enhanced sphere
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formation in normoxic cells (234), but they were unable to elucidate a mechanism
describing how hypoxic exosomes promote stemness in normoxic cells. More recently,
hypoxia was demonstrated to alter miRNA profiles in cancer-derived exosomes.
Furthermore, exosomes have been shown to reprogram cancer cells, genetically and
metabolically, through the delivery of their miRNA payload (233). In breast cancer,
hypoxic exosomes containing elevated levels of miR-210 increased migration and
proliferation in recipient cancer cells (228). In hypoxic tumors, miR-210 is directly
regulated by HIF -1α at its HRE and is involved in driving metabolic changes,
angiogenesis, cell proliferation, migration, invasion, apoptosis and stemness (210).
The role of hypoxia regulated exosomes and miRNA in EWS is currently
unknown and highlights a major gap in scientific knowledge. Therefore, we sought to
evaluate the role of hypoxic EWS-derived exosomes on the formation of stem-like cells
and tumorigenicty in EWS. We hypothesized that the transfer of hypoxic derived
exosomal miR-210 to normoxic cells targets the proapoptotic member caspase-8associated protein 2 (CASP8AP2), resulting in increased sphere formation and survival.

Results
To determine whether hypoxia promotes stemness in EWS cells, we measured
the effects of hypoxia on sphere formation and induction of stemness markers in EWS
cells. EWS cells cultured under hypoxic conditions formed significantly more spheres
than cells cultured under normoxia (21% O2) (Figure 4.1A) (310). Hypoxic spheres
expressed significantly elevated levels of miR-210 (Figure 4.1B) (310) and ESC genes
SOX2, OCT4 and NANOG compared to normoxic spheres (Figure 4.1C). Upregulation
of the ESC program in hypoxic spheres indicates an enrichment of stem-like cells. In
hypoxic spheres, the observed decrease in MYC is supported by a previous report in
hypoxic prostate cancer cells demonstrating similar inhibition in MYC expression (120).
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Previously, miR-145 was shown to be epigenetically repressed in primary EWS CSCs
and spheres compared to non-CSCs and cells grown in adherent cultures with FBS
(104). Consistent with recent findings, we observed miR-145 to be significantly
decreased in our EWS spheres compared to adherent cells (Figure 4.1D). Together,
these findings suggest that hypoxia enhances the stem-like phenotype in EWS cells.
We next investigated whether hypoxic exosomes promoted stemness in EWS
cells outside of a hypoxic environment, we co-cultured EWS NormoxicEXO and
HypoxicEXO with normoxic cells in a sphere-forming assay. EWS cells cultured under
normal oxygen tension levels demonstrated enhanced sphere formation after adding
HypoxicEXO (Figure 4.2) (310). SK-ES-1 HypoxicEXO enhanced sphere formation 3.7-fold
while A673 HypoxicEXO increased sphere formation by 2.2-fold compared to the effect of
their respective NormoxicEXO on normoxic cells. These results suggest that HypoxicEXO
could enhance stemness in normoxic EWS cells (310).
Based on our previous finding demonstrating that HypoxicEXO can enhance
sphere formation (234), we hypothesized that HypoxicEXO can increase tumor formation.
This rationale is supported by earlier studies showing EWS cells that are capable of
forming spheres in vitro to have enhanced in vivo tumor initiating abilities. To determine
if HypoxicEXO can enhance tumor formation, we injected NSG mice subcutaneously with
EWS (1 X 105) cells. Normoxic and hypoxic exosomes (20 µg) were injected bi-weekly
into the tumor site. Xenograft mice injected with HypoxicEXO formed significantly bigger
tumors than the other groups (Figure 4.3A). Interestingly, there was no difference in
tumor growth between normoxic control and NormoxicEXO mice. To determine if this
HypoxicEXO mediated affect on tumor formation correlated with an increase in EWS
CSCs, we disaggregated our tumors and assessed the EWS CSC marker, CD133, using
FACS analysis (Figure 4.3C). HypoxicEXO exosomes increased the CD133 population
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1.5-fold compared to PBS control tumors. No difference in CD133+ cells was observed
between PBS controls and NormoxicEXO treated mice. Recently in breast cancer studies,
hypoxic exosomes carrying miR-210 increased angiogenesis and proliferation in
xenograft mice (228). Consistent with these findings, we observed increased CD31 and
Ki67 staining in mice injected with HypoxicEXO (Figure 4.3B). Together, our findings
suggest HypoxicEXO can enhance tumor formation and moreover, this effect on tumor
growth may be the result of exosomal miR-210 stimulating EWS tumor initiating cells
and angiogenesis.
Since HIF-1α has been shown to regulate the expression of miR-210 in hypoxic
cells, we evaluated whether miR-210 levels in hypoxic EWS cells and their HypoxicEXO
were HIF-1α dependent by knocking down HIF-1α using siRNAs (siHIF-1α) (Figure 4.4A)
(310). In our HIF-1α knockdown cells, we observed a significant decrease in HIF-1α
under hypoxic conditions. Knockdown of HIF-1α significantly decreased miR-210 in both
our hypoxic cells (Figure 4.4B) and in their HypoxicEXO (Figure 4.4C) (310). In addition,
miR-210 levels in the HIF-1α knockdown cells and exosomes were similar to their
normoxic controls. These results indicate that miR-210 expression in hypoxic EWS cells
and HypoxicEXO is regulated by HIF-1α. Next, we assessed the effect of HypoxicEXO
derived from siHIF-1α cells on sphere formation (Figure 4.4D) (310). Here, HypoxicEXO
derived from siHIF-1α cells failed to increase sphere formation compared to control
HypoxicEXO. Together, these findings suggest that the stabilization of HIF-1α in hypoxic
cells play a significant role in the HypoxicEXO mediated effects on sphere formation (310).
Recent EWS studies implemented PI3K inhibitors to show that Akt signaling
stabilized HIF-1α and promoted chemoresistance (226). In another study, activated Akt
was demonstrated to regulate miR-210 in hypoxia dependent and independent ways
(209), however, it remains unclear how Akt regulates miR-210 under normoxic
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conditions. To determine the role of Akt signaling in regulating HIF-1α and miR-210, we
first treated our EWS cells with an Akt inhibitor at sub-IC50 concentrations. A673 and
SK-ES-1 were treated with MK-2206 (3 µM and 1 µM, respectively) for 48 hours under
normoxic and hypoxic conditions. In both cell lines, MK-2206 treatment groups
demonstrated complete inhibition of Akt phosphorylation compared to their normoxic and
hypoxic DMSO controls (Figure 4.5A). Consistent with previous studies (226), we
observed partial knockdown of HIF-1α in our hypoxic EWS cells treated with MK-2206.
MK-2206 treatment significantly decreased miR-210 expression in our EWS cells under
both normoxic and hypoxic conditions (Figure 4.5B). Hypoxic EWS cells treated with
MK-2206 only partially decreased miR-210 levels compared to their hypoxic controls,
and moreover, hypoxic A673 and SK-ES-1 treatment groups displayed ~20- and ~15fold increases in miR-210 compared to their normoxic controls. These findings are
supported by previous reports showing Akt regulation of miR-210 in HIF-1α dependent
and independent ways. Interestingly, miR-210 levels were unaffected in NormoxicEXO
derived from MK-2206 treated cells, while only a partial decrease in miR-210 was
observed in exosomes derived from hypoxic cells treated with the Akt inhibitor (Figure
4.5C). Next, we assessed the effect of HypoxicEXO derived from MK-2206 treated cells on
sphere formation (Figure 4.5D). Exosomes derived from hypoxic EWS cells treated with
MK-2206 significantly increased the number of spheres formed compared to normoxic
control cells and exosomes, however, they failed to form as many spheres as the control
HypoxicEXO. Together, these findings suggest that the Akt signaling in hypoxic cells play
a significant role in the HypoxicEXO mediated effects on sphere formation.
To study if miR-210 is required for sphere formation in EWS cells, we knocked
down miR-210 using inhibitors and overexpressed miR-210 using mimics (Figure 4.6A,
C) (310). Inhibition of miR-210 in hypoxic spheres resulted in a significant decrease in
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sphere formation in both EWS cell lines, however, while the number of spheres formed
in hypoxic SK-ES-1 knockdown cells was similar to normoxic spheres, hypoxic A673
knockdown cells had an elevated sphere formation compared to their normoxic spheres.
The overexpression of miR-210 in normoxic EWS cells promoted a 9-fold and 2-fold
increase in spheres formed in A673 and SK-ES-1 cells, respectively. Normoxic spheres
transfected with miR-210 inhibitors or combined mimics with inhibitors demonstrated no
significant change in sphere formation in either EWS cell line (310).
To evaluate the role of miR-210 in HypoxicEXO mediated sphere formation, we
treated normoxic EWS cells with HypoxicEXO alone and in the presence of cells
transfected with miR-210 inhibitors (Figure 4.6C) (310). The effects of HypoxicEXO on
sphere formation were significantly impaired in both A673 and SK-ES-1 cells treated with
the miR-210 inhibitor. Together, these results indicated that miR-210 in hypoxic spheres
and HypoxicEXO plays a causal role in increasing stemness in EWS cells (310).
To identify a functional mechanism underlying the effects of miR-210 on sphere
formation, we analyzed a miR-210 target gene, the proapoptotic member CASP8AP2. In
hypoxic EWS spheres, expression of CASP8AP2 was significantly decreased compared
to normoxic spheres and inhibition of miR-210 in hypoxic spheres restored CASP8AP2
expression when compared to normoxic spheres (Figure 4.6B) (310). Overexpression of
miR-210 decreased CASP8AP2 in normoxic spheres when compared to normoxic
controls (Figure 4.6D) (310). Importantly, normoxic spheres treated with HypoxicEXO
decreased CASP8AP2 levels, while miR-210 reversed the exosome mediated
downregulation of CASP8AP2 (Figure 4.6D) (310).
To demonstrate a direct effect of CASP8AP2 expression on sphere formation, we
knocked down CASP8AP2 using siRNAs (Figure 4.7A) (310). CASP8AP2 knockdown
led to significant increases in sphere formation in normoxic cells but had little effect on
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hypoxic spheres when compared to hypoxic controls (Figure 4.7B) (310). To further
investigate the functional role of CASP8AP2 in the survival of EWS spheres, we
assessed apoptosis using Annexin V/PI staining and flow cytometry (Figure 4.7C) (310).
Inhibition of CASP8AP2 in normoxic spheres significantly reduced apoptosis compared
to normoxic controls in both cell lines. Interestingly, SK-ES-1 hypoxic control and
CASP8AP2 knockdown spheres had similar reductions in apoptosis as the normoxic
CASP8AP2 knockdowns, whereas, A673 hypoxic controls demonstrated a further
decrease in apoptosis compared to normoxic CASP8AP2 knockdowns. Moreover,
CASP8AP2 knockdown further decreased apoptosis in hypoxic spheres compared to the
hypoxic control group. Our findings suggest that HypoxicEXO mediated delivery of miR210 to normoxic EWS spheres targets CASP8AP2 and promotes survival and stemness
in EWS cells (310).
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Figure 4.1: Hypoxia increases sphere formation, miR-210 and ESC genes in EWS
cells. (A) Sphere assay of A673 and SK-ES-1 cells grown under normoxic and hypoxic
conditions. Quantification of spheres was performed (magnification, X4) (mean+ SEM,
n=3, *, P<0.02, **, P<0.008). (B) Analysis of miR-210 expression levels in normoxic and
hypoxic A673 and SK-ES-1 spheres using qRT-PCR (Mean + SEM, n=3, *, P<0.5).
RNU6B was used as a control to normalize miRNA expression. (C) Differential
expression of ESC genes SOX2, OCT4, NANOG and MYC in normoxic and hypoxic SKES-1 spheres assessed by qRT-PCR. GAPDH was used as the endogenous control
(Mean + SEM, n=3 *, P<0.05, **, P<0.005). (D) EWS epigenetic stemness marker miR145 was measured by qRT-PCR in A673 and SK-ES-1 cells grown as adherent cells and
spheres under normoxic and hypoxic conditions.
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Figure 4.2: HypoxicEXO enhance sphere formation in EWS cells. A673 and SK-ES-1
EWS cells were cultured in normoxic conditions with 20 µg/ml of their respective
normoxic and hypoxic exosomes in a sphere assay. Quantification of spheres was
performed (magnification, X10) (Mean+ SEM, n=3, *, P<0.0008, **, P<0.003).
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Figure 4.3: HypoxicEXO increases stemness in EWS tumors. (A) Tumor growth curve
of SK-ES-1 xenograft mice. (B) Representative IHC analysis for CD31, CD99 and Ki67
in SK-ES-1 mice injected bi-weekly with normoxic and hypoxic SK-ES-1 exosomes. (C)
(Left) Represenative FACS analysis for CD133 disaggregated xenograft tumors. (Right)
Quantitative CD133 FACS analysis.
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Figure 4.4: HIF-1α Regulates HypoxicEXO miR-210 and mediates exosomal induced
sphere formation. (A) Western blot of HIF-1α in hypoxic A673 and SK-ES- cells
transfected with Non-Targeting control (NTC) and HIF-1α-siRNA. α-Tubulin was used as
the internal loading control. (B) Analysis of miR-210 expression levels in A673 and SKES-1 cells transfected with NTC and HIF-1α-siRNA, and (C) their respective exosomes
using qRT-PCR (Mean + SEM, n=3, *, P<0.02, **, P<0.05, ***, P<0.0002). RNU6B and
miR-16 was used as a control to normalize miRNA expression in cells and exosomes,
respectively. (D) Assessment of sphere formation in A673 and SK-ES-1 EWS cells
cultured in normoxic conditions with 20 µg/ml normoxic and hypoxic exosomes derived
from their respective cells transfected with NTC and HIF-1α-siRNA. Quantification of
spheres was performed (Mean+ SEM, n=3, *, P<0.0004, **, P<0.0001).
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Figure 4.5: Akt regulates miR-210 in HIF-1α dependent and dndependent ways and
mediates HypoxicEXO-induced sphere formation. (A) Western blot of HIF-1α, pAKT
and Akt in hypoxic A673 and SK-ES- cells treated with MK-2206. α-Tubulin was used as
the internal loading control. (B) Analysis of miR-210 expression levels in A673 and SKES-1 cells treated with MK-2206, and (C) their respective exosomes using qRT-PCR
(Mean + SEM, n=3, *, P<0.05). RNU6B and miR-16 was used as a control to normalize
miRNA expression in cells and exosomes, respectively. (D) Assessment of sphere
formation in A673 and SK-ES-1 EWS cells cultured in normoxic conditions with 20 µg/ml
normoxic and hypoxic exosomes derived from their respective cells treated with DMSO
or MK-2206. Quantification of spheres was performed (Mean+ SEM, n=3, *, P<0.05).
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Figure 4.6: miR-210 regulates sphere formation by targeting CASP8AP2. (A)
Sphere assay quantifying A673 and SK-ES-1 cells transfected with either miR-scramble
or miR-210 inhibitors under normoxic and hypoxic conditions. (Mean + SEM, n=3, *,
P<0.0001, **, P<0.005). (B) Western blot of CASP8AP2 in A673 and SK-ES-1 Spheres
transfected with either miR-scramble or miR-210 inhibitors under normoxic and hypoxic
conditions. (C) Sphere assay quantifying A673 and SK-ES-1 cells transfected with miRscramble, miR-210 mimics, miR-210 inhibitors or 20 µg/ml hypoxic exosomes. (Mean +
SEM, n=3, *, P<0.002, **, P<0.0001). (D) Western blot of CASP8AP2 in A673 and SKES-1 spheres transfected with miR-scramble, miR-210 mimics, miR-210 inhibitors or 20
µg/ml hypoxic exosomes.
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Figure 4.7: CASP8AP2 knockdown promotes sphere formation by enhancing
survival. (A) A673 and SK-ES-1 spheres transfected with Non-Targeting control (NTC)
or CASP8AP2-siRNA. α-Tubulin was used as the internal loading control. (B) Sphere
assay quantifying A673 and SK-ES-1 cells transfected with either NTC or CASP8AP2siRNA under normoxic and hypoxic conditions. (Mean + SEM, n=3, *, P<0.002, **,
P<0.0002, ***, P<0.0001). (C) Assessment of apoptosis by Annexin V-FITC/PI staining.
(Left) Representative plots and (Right) Quantification of Annexin V-FITC stainined A673
and SK-ES-1 spheres transfected with NTC or CASP8AP2-siRNA under normoxic and
hypoxic conditions. (Mean + SEM, n=3, *, P<0.0008, **, P<0.0001).
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Discussion
The hypoxic TME is considered a crucial driver of tumor development and
therapy resistance. Aggressive tumors often consist of hypoxic regions capable of
creating an environment that supports stem-like cancer cells (120, 294). In EWS,
hypoxia and enrichment of stem-like cells is associated with poor patient outcomes (112,
296). Mounting evidence suggests that the hypoxic niche may be able to exert its effects
beyond the local microenvironment by signaling to nearby normoxic tumor cells (233).
Exosomes have been described as critical mediators of cell-cell communication within
the TME and may provide an explanation for how hypoxia contributes to tumors with an
aggressive phenotype. Our findings indicate that exosomes secreted under hypoxic
conditions significantly increase sphere formation in normoxic EWS cells. Moreover, we
show that Akt and HIF-1α regulates the HypoxicEXO mediated effect on sphere formation
by enriching miR-210 within the hypoxic derived exosomes. We demonstrate that the
delivery of miR-210 to recipient cells enhances stemness in EWS cells by silencing a
potential target, the proapoptotic member CASP8AP2, that is critical to the survival of
stem-like cells (310).
Recently, a growing body of evidence has shown that exosomes function as a
bridge between neighboring cancer cells by delivering an RNA rich cargo (233, 236,
297). In hypoxic tumors, exosomes have been suggested to contribute to the aggressive
phenotype by mediating the cross-talk between tumor cells in hypoxic regions and target
cells in normoxic regions (233, 234). However, the association between hypoxia and
exosomes in EWS has yet to be explored.
Increasing efforts are being made in elucidating the mechanism’s underlying
exosomal miRNAs silencing of target mRNAs in recipient cells, prompting our
investigation into the miRNA profile in EWS exosomes. Recent studies in breast cancer
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revealed exosomal miRNA promoted tumorigenesis in a Dicer-dependent manner and
moreover, Dicer was demonstrated to facilitate miRNA processing from pre-miRNA to
mature miRNA in exosomes resulting in stable miRNA capable of exerting long lasting
pro-tumorigenic effects in recipient cells (264). In our study, we initially demonstrated
that HypoxicEXO carrying hypoxia regulated miRNAs enhanced tumor formation and
increased the EWS stem cell-like CD133+ subpopulation. Several studies have identified
mechanisms describing the effects of HypoxicEXO miRNA cargo in angiogenesis,
metastasis, proliferation, migration and invasion (232, 233), but it is currently unknown
how HypoxicEXO delivery of miRNA influences stemness in recipient cells. A previous
study indicated exosomes derived from hypoxic prostate cancer cells can enhance
sphere formation in normoxic cells (234), however, the underlying molecular mechanism
remains unclear. Since HIF-1α is a primary regulator of the hypoxic response, an early
study reported enrichment of miR-21 in exosomes derived from hypoxic oral squamous
cell carcinoma cells was directly regulated by stable HIF-1α (233). In EWS and multiple
other studies, Akt signaling has been shown to stabilize and amplify the HIF-1α
mediated response to hypoxia (195, 226). In our study, we demonstrate that the effects
of HypoxicEXO on sphere formation in normoxic EWS cells is regulated by Akt and HIF-1α
remodeling of the HypoxicEXO miRNA cargo and directly enriching for miR-210 (310).
This is supported by our observations showing HypoxicEXO derived from HIF-1α
knockdown and MK-2206 treated cells failed to increase sphere formation compared to
normoxic control spheres and spheres co-cultured with NormoxicEXO. Interestingly, our
findings suggest that packaging of miR-210 into hypoxic exosomes is primarily regulated
by the stabilization HIF-1α by Akt, moreover, our studies indicate that Akt enriches
exosomal miR-210 by amplifying HIF-1α activity. Given that miR-210 was highly
expressed in both our hypoxic cells and exosomes, we are the first to show that
increased miR-210 levels in HypoxicEXO are dependent on HIF-1α stabilization (310).
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Together, this evidence compelled us to investigate the role of cellular and exosomal
miR-210 in promoting stemness in EWS cells (310).
It is well established that a myriad of miRNAs are capable of targeting
overlapping mRNA in cells, especially in recipient cells that have internalized cancer
derived exosomes (244, 264, 278). Our observed effects of HypoxicEXO miRNA content
on normoxic spheres might not be the result of a single miRNA, however, our findings
indicate that miR-210, is at least one miRNA capable of mediating sphere formation in
hypoxic spheres and in spheres co-cultured with HypoxicEXO (310). Previously,
knockdown of miR-210 in hypoxic glioma stem cells was demonstrated to decrease
sphere formation and the overall stem cell phenotype (223). In osteosarcoma stem cells,
miR-210 overexpression and knockdown studies revealed that miR-210 can promote
stemness and even reprogram differentiated osteosarcoma cells into Stro-1+/CD117+
stem cells (221). Our study also demonstrated that inhibition of miR-210 could reduce
sphere formation in hypoxic spheres (310). Moreover, when we overexpressed miR-210
in normoxic EWS spheres, it resulted in increased sphere formation consistent with
previous studies demonstrating a miR-210 mediated effect on cellular reprogramming
(221). Importantly, we are the first to show in EWS that hypoxia increases sphere
formation and in part, sphere formation is regulated by miR-210 expression (310). In
breast cancer, hypoxic derived exosomal miR-210 promoted angiogenesis and
proliferation in xenograft tumors (228). Delivery of HypoxicEXO to normoxic cells in our
study indicated that exosomal miR-210 can promote sphere formation. Furthermore, we
show that miR-210 can enhance stemness by targeting CASP8AP2 (310).
This is the first study to describe a mechanism where the miRNA cargo in
HypoxicEXO target a gene involved in regulating the survival of stem-like cells. In hypoxic
bone marrow derived mesenchymal stem cells (BM-MSC), miR-210 targeted and

107
silenced CASP8AP2, resulting in an antiapoptotic affect that bolstered the survival of the
BM-MSCs (222). CASP8AP2 is a proapoptotic member that participates in fas-induced
and tumor necrosis factor-α- mediated apoptosis signaling (224). Since EWS cells are
thought to derive from transformed BM-MSCs, we chose to investigate if EWS cells can
adopt this prosurvival pathway to preserve its stem-like population. Consistent with
previous findings, knockdown of miR-210 in our hypoxic spheres resulted in increased
CASPA8AP2 expression, while overexpression of miR-210 in normoxic spheres inhibited
CASP8AP2 levels (222, 225). HypoxicEXO delivering miR-210 demonstrated a similar
decrease in CASP8AP2 expression in normoxic spheres. Our data suggest that sphere
formation is negatively regulated by CASP8AP2 activity. This is supported in our
CASP8AP2 knockdown spheres demonstrating significant increases in sphere formation
in the normoxic group and slight increases in the hypoxic group. Furthermore,
knockdown of CASP8AP2 significantly decreased apoptosis in normoxic spheres. In our
hypoxic spheres, CASP8AP2 correlated with a significant decrease in apoptosis,
suggesting that hypoxia induces prosurvival mechanisms that are crucial for sphere
formation. Supportive of our findings, previous EWS studies showed that resistance to
apoptosis in hypoxic cells was dependent on HIF-1α (144, 226). Together, these studies
indicate that CASP8AP2 silencing by miR-210 prevents apoptosis, promoting sphere
formation in hypoxic EWS cells and in normoxic cells pretreated with HypoxicEXO (310).
This study describes a mechanism whereby EWS cells under hypoxic conditions
release exosomes that enhance stemness in EWS cells. We identified a hypoxia
regulated miRNA significantly expressed in hypoxic cells and HypoxicEXO and
characterized a potential target that facilitates an apoptotic pathway critical to sphere
formation. Ongoing studies are investigating the role of HIF-1α on regulating EWS
stemness and together, our future aim is to investigate how HIF-1α selectively
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modulates the packaging of miRNAs into HypoxicEXO, and validate additional miRNAs
that promote aggressive hypoxic phenotypes (310).
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Chapter V
Exosomes Secreted under Hypoxia Activate Akt
signaling in Ewing’s Sarcoma Spheres and CancerAssociated Fibroblasts
Introduction
Significant importance has been placed on the role of the tumor
microenvironment (TME) in promoting tumor formation and how the interaction between
cancer cells and the TME can lead to relapse, metastasis and ultimately therapy
resistance (231). Targeting the TME in patients with aggressive malignancies is an
emerging area and remains an opportunity to develop new therapies. EWS tumors
display a diverse TME where 85% of patients are diagnosed with malignancies primarily
localized within bone, but in 15% of patients, EWS arises within extra-osseous soft
tissues. Moreover, aggressive tumors develop metastatic lesions in the lungs and at
distant boney sites (298). This TME consists of tumor cells, osteoblasts, osteoclasts,
myeloid cells, endothelial cells, mesenchymal cells and cancer-associated fibroblasts
(CAFs) within normoxic and hypoxic regions. Acellular components of the TME consists
of extracellular matrix, various soluble factors and extracellular vesicles that support the
tumor niche (231).
Uptake of exosomes derived from cancer cells induces epigenetic changes in
target cells that play a significant role in tumor growth, progression, metastasis, drug
resistance, angiogenesis and induction of pre-metastatic niches (244). These
protumorigenic effects are mediated not only through cross-talk between cancer cells,
but between cancer cells and their surrounding stroma (230). More recently, Ramteke et
al reported that exosomes secreted from hypoxic prostate cancer cells transformed
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fibroblasts into CAFs and enhanced stemness in naïve prostate cancer cells (234),
however, the effect that hypoxic exosomes had on inducting stem-like cells remains
unclear in this study due to lack of rigor in characterizing the stem cell phenotype.
CAFs have been observed to promote tumor formation and metastasis within the
TME and support the pre-metastatic niche (279). Recent evidence suggests exosomes
can reprogram fibroblasts into CAFS (236). In EWS, the role of exosomes in
reprogramming cancer cells into stem-like and transforming fibroblasts is unknown.
Furthermore, it is unclear in any cancer model whether a hypoxic TME can modulate
exosomes capable of inducing stem cell formation consistent with an established
molecular CSC phenotype in their respective cancer field, and whether reprogramming
of fibroblasts into CAFs can lead to a transformed tumorigenic phenotype.
In this study, we hypothesized that EWS cells under hypoxic conditions release
exosomes that activate Akt in EWS spheres and transform fibroblasts that demonstrate
an elevated tumorigenic CAF phenotype. Our observations strongly suggest that the Akt
signaling pathway is a likely contributor to these effects and therefore, may underly an
important mechanism that could explain the aggressiveness and poor outcomes
associated with hypoxic tumors. Our findings indicate that HypoxicEXO mediated delivery
of multiple miRNA with overlapping and redundant targets that could be responsible for
activating Akt in EWS spheres and transformed CAFs.

Results
To test whether hypoxic exosomes promote a stem-like phenotype in EWS cells
outside of a hypoxic environment, we co-cultured EWS NormoxicEXO and HypoxicEXO with
normoxic cells in a sphere-forming assay. As previously shown, EWS cells cultured
under normal oxygen tension levels demonstrated enhanced sphere formation after
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adding HypoxicEXO (Figure 4.2). We further assessed the effect of EWS HypoxicEXO on
the stem-like phenotype in EWS cells by measuring the expression of ESC genes
(Figure 5.2B). HypoxicEXO increased Sox2, Oct4 and Nanog protein expression
compared to normoxic control cells, however, no significant effect was observed on Myc
expression. Interestingly, NormoxicEXO demonstrated a similar effect when compared to
normoxic controls, however, HypoxicEXO had a more significant effect on Sox2 and
Nanog, but no significant difference was observed in Oct4 and Myc expression between
exosome groups. Based on our network analysis indicating that the miRNA cargo in
HypoxicEXO target mRNAs involved in regulating Akt signaling (Figure 3.7B), we
investigated the status of activated Akt in EWS cells treated with NormoxicEXO and
HypoxicEXO. Consistent with the interactome predictions (Figure 3.7B), HypoxicEXO
significantly increased phosphorylated Akt levels in EWS spheres compared to both
normoxic spheres and spheres cultured with NormoxicEXO (Figure 5.2A). Akt signaling
was elevated the most in hypoxic control spheres (Figure 5.1) which was expected since
activated Akt is enhanced under hypoxic conditions and in TICs (195, 299, 300).
To evaluate whether HypoxicEXO activate Akt signaling in vivo, we injected NSG
mice with SK-ES-1 cells and proceeded to inject the mice intratumorally with
NormoxicEXO and HypoxicEXO for a period of 6 weeks. Tumors were subjected to
mechanical and enzymatic disaggregation. HypoxicEXO treated tumors displayed
significantly elevated phosphorylated Akt levels (Figure 5.3) similar to the in vitro
observations. Together, these findings suggest HypoxicEXO delivery of enriched miRNAs
targeting the Akt signaling pathway introduces a potential underlying mechanism
responsible for the effects of HypoxicEXO on normoxic EWS cells.
To examine whether EWS-derived HypoxicEXO enhance reprograming of
fibroblasts into CAFs, NIH3T3 fibroblasts were co-cultured with NormoxicEXO and
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HypoxicEXO in a soft agar assay to assess anchorage-independent growth. The ability of
cells to form colonies in a soft agar assay indicates transformation and potentially
tumorigenic capabilities (301). HypoxicEXO derived from both A673 cells significantly
enhanced colony formation 1.68 fold while SK-ES-1 HypoxicEXO increased colony
formation 1.62 fold compared to their respective NormoxicEXO (Figure 5.4A). Expression
of the CAF marker alpha smooth muscle actin (α-SMA) (234) was assessed in NIH3T3
cells co-cultured with SK-ES-1 exosomes over a timecourse. HypoxicEXO increased
expression of α-SMA 1.5 fold compared to NormoxicEXO (Figure 5.4B). NormoxicEXO
induce colony formation and slight expression of α-SMA in NIH3T3 cells as well,
indicating a transformation effect. Together, these data suggests that HypoxicEXO
enhance fibroblast reprogramming into CAF cells.
To address the tumorigenic effects of EWS-derived exosomes on NIH3T3
fibroblasts, we conditioned NIH3T3 cells with SK-ES-1 NormoxicEXO and HypoxicEXO for
72 hrs and mixed the exosomes with NIH3T3 cells prior to injecting NSG mice. We
observed increased tumor formation in NIH3T3 tumors treated with HypoxicEXO
compared to NormoxicEXO and control treated mice (Figure 5.5A). All mice injected with
NIH3T3 cells conditioned with HypoxicEXO formed tumors while mice injected with
NIH3T3 control cells or NIH3T3 mixed with NormoxicEXO formed 4/5 tumors. The control
group formed tumors indicating the intrinsic tumorigenic potential of the cell line. As
predicted by our interactome analysis (Figure 3.7B), activated Akt was significantly
increased in tumors preconditioned with HypoxicEXO compared to untreated and
NormoxicEXO treated groups (Figure 5.5B). H&E staining in tumors demonstrated a
spindle shape cell morphology in all groups (Figure 5.5C). Tumors pretreated with
HypoxicEXO demonstrated a similar increase in α-SMA consistent with the in vitro co-
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culture studies. This suggests EWS HypoxicEXO enhance tumorigenicity in NIH3T3 cells
with activated Akt signaling.
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Figure 5.1: Hypoxia activates Akt in EWS spheres. Protein expression of IGF1R
signaling pathway. IGF1R, p-Akt, Akt, p-mTORC1, mTORC1, p-ERK and ERK were
assessed by western blot in A673 and SK-ES-1 normoxic and hypoxic spheres. αTubulin was used as a loading control in western blots.
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Figure 5.2: HypoxicEXO increase Akt and ESC gene expression in EWS spheres. (A)
Akt and p-Akt was assessed by immunoblot in normoxic SK-ES-1 spheres co-cultured
with 20 µg/ml SK-ES-1 NormoxicEXO and HypoxicEXO . SK-ES-1 normoxic and hypoxic
spheres were used as controls. α-Tubulin was used as a loading control in western blots.
(B) Protein expression of embryonic stem cell genes and EWS markers Myc, Oct 3/4,
Nanog and Sox2 were assessed by western blot in SK-ES-1 normoxic and hypoxic
control spheres and normoxic spheres co-cultured with NormoxicEXO and HypoxicEXO.
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Figure 5.3: HypoxicEXO increase Akt in EWS tumors. Immunoblot assessing Akt and
p-Akt in SK-ES-1 tumors. α-Tubulin was used as a loading control in western blots.
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Figure 5.4: HypoxicEXO enhances reprograming in NIH3T3 cells. (A) Anchorage
independent growth in NIH3T3 cells co-cultured with increasing amounts (0, 5, 10, 20
µg/ml) of normoxic and hypoxic SK-ES-1 and A673 exosomes in a soft agar assay.
Quantification of spheres was performed (magnification, X20) (mean+ SEM, n=3, *,
p<0.05, **, p<0.001, ***, p<0.0001). (B) Western blot of CAF marker, α-SMA, was
assessed in NIH3T3 cells treated with 20 µg normoxic or hypoxic SK-ES-1 exosomes
(time points: 24 and 48 hrs). α-tubulin was used as the internal loading control for
normalization.
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Figure 5.5: HypoxicEXO enhance NIH3T3 tumorigenicity. (A) NIH3T3 cells were cocultured with PBS, SK-ES-1 NormoxicEXO and HypoxicEXO as described in Materials and
Methods. NIH3T3 cells were harvested after 72 hrs and mixed with either PBS or 20 µg
SK-ES-1 NormoxicEXO and HypoxicEXO and injected into NSG mice. (mean+ SEM, *,
p<0.05). Tumorigenicity and tumor growth assessed every day until tumors reached 1
cm3. (B) Western blot pAkt and Akt expression in formed NIH3T3 tumors, α-tubulin was
used as the internal loading control for normalization. (C) Representative H&E (Top) and
α-SMA stained (Bottom) NIH3T3 tumors treated with PBS (Vehicle) NormoxicEXO and
HypoxicEXO . Relative staining intensity was quantified using ImageJ (mean+ SEM, *,
p<0.000001).
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Discussion
The hypoxic TME is widely considered as a crucial driver in tumorigenesis and
therapy resistance. Aggressive tumors often consist of hypoxic regions capable of
creating an environment that supports stem cell-like TICs (120, 294). In EWS, hypoxia
and enrichment of TICs is associated with poor patient outcomes (112, 296). Mounting
evidence suggests that the hypoxic niche may be able to exert its effects beyond the
local microenvironment by signaling to nearby normoxic tumor cells and the surrounding
stroma (233). Exosomes have been described as critical mediators of cell-cell
communication within the TME and may provide an explanation for how hypoxia
contributes to tumors with an aggressive phenotype (233). Our findings indicate that
hypoxia and exosomes secreted under these conditions may be one of the underlying
mechanisms responsible for inducing TIC-like formation in EWS cells and
reprogramming fibroblasts into CAFs with enhanced tumorigenicity.
Regions within tumors experiencing long-lasting hypoxia result in necrosis and
are linked to poor patient survival. A clinical study in EWS reported primary tumors with
necrotic regions that correlated with the worst overall survival in patients who had an
increased chance for metastasis (296). In prostate cancer, stabilization and activation of
the HIFs under chronic hypoxia has been shown to increase sphere formation and
induce expression of ESC genes (120). In primary EWS tumors, the isolated TIC
subpopulation displayed increased ESC expression and the ability to grow as spheres
with resistance to doxorubicin (14, 112), however, it has been unclear how hypoxia
impacts stemness in EWS. In this present study, prolonged hypoxia enhanced sphere
formation in EWS cells and upregulated the ESC genes SOX2, OCT4 and NANOG.
These results are the first in EWS describing the role of hypoxia in promoting a TIC-like
phenotype consistent with EWS TICs.
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It is well established that the internalization of cancer derived exosomes into
recipient cells introduces a miRNA capable of interacting with the same mRNA in the
host cell that elicit similar oncogenic effects (244, 264, 278). Network analysis of our
miRNA cargo revealed enrichment of eight miRNAs (miR-19b-3p, miR-92a-3p, miR-25,
miR-181a-5p, miR-27a-3p, miR-29b-39 and miR-30c-5p) in our HypoxicEXO that all
converge on the Akt signaling pathway. In addition, differential expression of the
exosomal miRNA revealed elevated levels of the hypoxia regulated miRNA, miR-10b, in
HypoxicEXO. Previous studies indicate that these miRNAs activate Akt by directly
silencing gene expression of proteins involved in negatively regulating the Akt pathway
(302-309), however, only miR-19b-3p has been shown to affect Akt signaling via
exosome mediated transfer to target cells. These findings suggest a broader and more
intricate regulatory network which may underly the effects observed in EWS TICs and
CAFs treated with EWS HypoxicEXO.
Functionally, the delivery of HypoxicEXO miRNA have been demonstrated to
enhance migration and invasion in normoxic cancer cells (233), however, the capability
of HypoxicEXO miRNA to regulate TIC formation is unknown. Our in vitro findings revealed
HypoxicEXO significantly enhanced sphere formation and ESC expression of Sox2, Oct4
and Nanog compared to the normoxic control. Interestingly, NormoxicEXO displayed a
similar result but to a lesser extent than the HypoxicEXO. Moreover, no difference was
observed in Oct4 expression between exosome treated spheres. Exosomes derived
from hypoxic prostate cancer cells demonstrated a similar HypoxicEXO mediated effect on
sphere formation (234), but did not further characterize an effect on stemness by
measuring ESC markers in the exosome treated spheres. Consistent with our miRNA
network analysis prediction, we showed that spheres treated with HypoxicEXO had
significant elevation of phosphorylated Akt indicating activation of the Akt signaling
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pathway. Similar effects were observed in our EWS spheres grown under hypoxia
suggesting Akt signaling as an underlying mechanism in EWS sphere formation. In vivo,
SK-ES-1 tumors treated with HypoxicEXO displayed a significant increase in the
transmembrane protein CD133 (Figure 4.3C), which has been previously reported as a
TIC marker in EWS tumors. Consistent with our sphere co-culture studies, tumors
treated with HypoxicEXO displayed similar activation in Akt signaling. The role of Akt
underlying the cancer stem cell phenotype is supported by studies in hypoxic glioma
cells demonstrating increased sphere formation, expansion of CD133+ glioma cancer
stem cells and elevated Akt signaling (195). Furthermore, abrogation of Akt in glioma
CD133+ cancer stem cells decreased tumor-initiation in a xenograft mouse model (227).
Here we are the first to report that HypoxicEXO enhance the TIC-like population in EWS
and together, our data suggests that the HypoxicEXO miRNA cargo may underly the
mechanism activating Akt signaling in EWS TICs.
Cancer-associated fibroblasts participate in the TME by supporting cancer cell
invasion, proliferation and metastasis (279) CAFs overexpress α-SMA compared to
normal fibroblasts and detection of α-SMA is generally used as a reliable CAF marker
(279). The mechanism describing how normal fibroblasts are reprogrammed into CAFs
is still unclear. However, mounting evidence suggests the CAFs arise from exosomes
secreted from cancer cells in the local TME (234) and currently, no studies in EWS have
reported an exosome mediated induction of the CAF phenotype. Exosomes secreted
from hypoxic prostate cancer cells induced expression of α-SMA in prostate fibroblasts,
suggesting that hypoxia enhances CAF reprogramming via an exosome mediated
process (234). Recently, breast cancer derived exosomes delivering miR-9 to human
breast fibroblasts was demonstrated to enhance the switch to CAFs (236). Another study
in breast cancer revealed the miRNA cargo in breast cancer derived exosomes
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transformed endothelial cells with tumorigenic capabilities (264). Based on the evidence
in these studies, we questioned whether exosomes could promote a CAF phenotype in
fibroblasts and moreover, could these transformed CAFs exhibit the ability to form
tumors in a xenograft model. In our in vitro studies, we observed enhanced anchorageindependent growth and increased expression of the CAF marker α-SMA in NIH3T3
fibroblasts treated with HypoxicEXO compared to NormoxicEXO treated cells. Similar to our
findings, a previous report demonstrated exosomes derived from colorectal cancer cells
induced α-SMA expression and anchorage-independent growth in recipient fibroblasts
(280). In vivo, we observed increased tumorigenicity in mice injected with fibroblasts
pretreated with HypoxicEXO, where control fibroblasts and NormoxicEXO pretreated
fibroblasts displayed significantly limited tumorigenic capabilities with 4/5 mice forming
tumors. Similar to our findings, an early EWS study reported that control NIH3T3
fibroblasts were unable to form colonies in vitro, but possessed limited tumor forming
abilities in mice (18). Recently, gastric cancer derived exosomes were shown to mediate
CAF induction by increasing Akt signaling (281) and in several other reports, activated
Akt signaling was observed to underly development and progression of malignant
fibrosarcoma (282, 283). In our tumors preconditioned with HypoxicEXO, they
demonstrated significantly elevated levels of α-SMA and phosphorylated Akt reflecting a
fibrosarcoma phenotype. These findings are further supported by our HypoxicEXO miRNA
network analysis predicting activating Akt signaling as a primary target in recipient cells.
Here we report for the first time an exosome mediated effect on CAF induction with
tumorigenic capabilities.
In conclusion, EWS cells under these hypoxic conditions release exosomes that
enhance the TIC-like phenotype in EWS cells and transform fibroblasts that demonstrate
an elevated tumorigenic CAF phenotype. Ongoing studies are investigating the role of
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hypoxia on selectively modulating the packaging of miRNAs into HypoxicEXO, and
validate the miRNAs involved in Akt activation leading to an aggressive hypoxic
phenotype.
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Chapter VI
General Discussion
Overview and Impact of Study
Currently, areas of exosome research are exploring the heterogeneity in size and
content of cancer exosomes. This knowledge is helping us better understand tumor
progression and the effects of therapies on cancer cells. Liquid biopsy techniques that
isolate patient serum exosomes and analyze exosomal DNA, RNA and protein are now
aiding in diagnosis, prognosis and the detection of minimal residual disease following
patient therapies. The findings presented in this dissertation contribute to the greater
body of knowledge in the exosome field and provides a new mechanism underlying the
functional effects of hypoxic exosomes on cells composing the TME. Moreover, this work
introduces an exosomal RNA profile that can be utilized to detect aggressive hypoxic
tumors in patients (244).
Given the existing challenges involved with current exosome isolation methods,
we first had to determine an optimal isolation approach that can reliably yield vesicles
consistent with exosomes and are suitable for functional studies. Our observations led
us to conclude that the standard exosome isolation method followed by microfiltration
yielded the highest quality of exosomes appropriate for downstream analysis and
functional studies. Further characterization of our normoxic and hypoxic exosomes
isolated using the standard approach revealed an RNA and protein profile that could be
utilized as biomarkers with diagnostic and prognostic potential. Importantly, the hypoxic
EWS exosomes demonstrated significantly elevated levels of EWS-FLI1 mRNA and
increased protein expression of EZH2, EWS-FLI1 and CD99. These findings can aid in
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both detection of EWS and potentially predict outcomes associated with hypoxic tumors.
Moreover, we are the first to report a molecular profile in hypoxic EWS exosomes.
When we performed RNA-seq analysis on our exosomes, we observed
differentially expressed mRNA and miRNA content between our normoxic and hypoxic
exosomes. Interestingly, the miRNA in the HypoxicEXO demonstrated a similar profile
compared to their parental hypoxic cells, suggesting HypoxicEXO may reflect the parental
tumor and could be used for prognostic purposes. Surprisingly, the mRNA expression
patterns in the HypoxicEXO failed to reflect their parental cells. Bioinformatical analysis of
our cellular and exosomal miRNA revealed miR-210 as the most significant and most
differentially expressed miRNA. Consistent with previous studies (228), this finding
suggests exosomal miR-210 as a prognostic indicator of hypoxic tumors. This is the first
report showing miR-210 in EWS exosomes.
IPA network analysis revealed both hypoxic exosomal mRNA and miRNA
networks that converge on the Akt signaling pathway. Prior to this discovery, we had
observed increased Akt signaling in hypoxic spheres, suggesting a regulatory role for
Akt activation in mediating stemness in EWS. However, our preliminary data (not shown)
using Akt inhibitors failed to decrease Akt phosphorylation and sphere formation in
hypoxic EWS spheres but was able to significantly inhibit Akt signaling and sphere
formation under normoxia. This finding indicated that hypoxic EWS spheres demonstrate
therapy resistance which prevented us from further analysis of Akt activity in hypoxic
spheres. We proceeded to test whether hypoxic exosomes affected Akt signaling in
EWS spheres and developing tumors. Both in vitro and in vivo exosome treatment
studies, HypoxicEXO significantly increased sphere and tumor formation as well as Akt
signaling. Moreover, both spheres and tumors treated with HypoxicEXO demonstrated
increased expression of ESC markers. This is the first evidence showing a HypoxicEXO
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mediated effect on stemness. In addition to the effect of HypoxicEXO on EWS cells, our
findings showed HypoxicEXO could enhance CAF formation in NIH3T3 cells by increasing
anchorage independent growth and α-SMA expression. Furthermore, in NSG mice
injected with NIH3T3 cells and EWS exosomes, HypoxicEXO stimulated Akt signaling and
increased tumor formation. These observations are the first to describe an exosomal
mediated effect on driving tumorigenesis in CAFs.
Based on the miRNA-seq analysis revealing miR-210 as the top miRNA
expressed in hypoxic EWS cells and their derived exosomes, we proceeded to
investigate miR-210 levels in hypoxic spheres. Not surprisingly, miR-210 was
significantly increased in hypoxic spheres and given hypoxia has been shown in our
study to increase sphere formation, miR-210 expression could be used as a prognostic
biomarker for hypoxic tumor cells with increased stemness. Further examination of the
hypoxic EWS spheres revealed elevated ESC gene expression and decreased miR-145
levels. This is the first finding in EWS demonstrating a stem-like phenotype associated
with hypoxia and hypoxically regulated miRNA. Moreover, the hypoxia mediated effect
on EWS spheres demonstrated a similar phenotype as primary EWS CSCs. Given that
hypoxic exosomes have been shown to propagate a phenotype outside their hypoxic
niche, we wondered if hypoxic exosomal miR-210 could underly the HypoxicEXO
mediated effects on sphere formation.
Initially, we observed normoxic EWS spheres co-cultured with HypoxicEXO
increased sphere formation and expression of ESC genes. In vivo, HypoxicEXO increased
tumor growth in NSG mice and enhanced expression of the EWS CSC marker CD133.
Immunohistochemistry staining revealed increased angiogenesis and profileration,
indicated by CD31 and Ki67 respectively. These observations are the first to describe a
HypoxicEXO mediated effect on stemness in vivo. In a previous study in breast cancer,
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hypoxic exosomes enriched with miR-210 resulted in significant increases in tumor
proliferation and angiogenesis using a xenograft mouse model. Together, this evidence
prompted us to further investigate the underlying exosomal miR-210 effects on stemness
in EWS and would be the first study to describe an exosomal mediated mechanism
responsible for enhancing stemness in cancer cells.
In an attempt to describe a comprehensive mechanism underlying how
HypoxicEXO facilitate the cross-talk between normoxic and hypoxic cells, and extend the
hypoxic stem-like phenotype beyond the hypoxic niche, we knocked down the hypoxia
master regulator, HIF-1α, in hypoxic EWS cells and measured the knockdown effect on
exosomal miR-210 expression on sphere formation. This approach revealed a HIF-1α
mediated effect on exosomal miR-210 packaging and moreover, exosomes derived from
HIF-1α knockdown cells failed to enhance sphere formation. Furthermore, we were able
to shown that exosomal miR-210 regulates EWS sphere formation by targeting the
proapoptotic member CASP8AP2. Together, this is the first report communicating an
axis whereby HIF-1α regulates exosomal miRNA packaging and as a result, drives a
stem-like phenotype in EWS cells by interfering with the apoptotic machinery. These
findings introduce a new survival mechanism in EWS responsible for promoting
stemness.

Limitations of Study and Future Work
The precise physiological functions of exosomes in cancer remain unclear.
However, in this study and others, the role of exosomes in facilitating intercellular crosstalk between cancer cells and cells that compose the TME are beginning to elucidate an
emerging mechanism for cell-to-cell communication (244). Currently, exosome functional
studies are limited mainly by in vitro experiments utilizing exosomes concentrations
considered to be rough approximations of physiological levels, but possibly may not be
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relevant in vivo. The exosome concentrations used in our work were determined by
using an exosome dose response in a sphere assay and the rationale for this approach
remains the standard in the field (289), however, this may not be physiological as
previously mentioned. This potential pitfall could be addressed by exploring the role of
exosomes in animal models where exosome secretion can be manipulated to assess the
physiological role of exosomes. In addition, an in vitro solution implementing a trans-well
assay could provide a more physiological model for intercellular signaling, but limits
downstream applications.
One of the biggest pitfalls often reported in exosome research is the comparison
of the molecular profiles (RNA or protein) between exosomes and their parental cells.
These comparisons can be useful when trying to determine the selective packaging of
exosomal cargo, however, at best, this approach can be helpful as a fishing experiment
when trying to find novel molecules or determine if the exosomes represent a similar
profile that represents the cell of origin. The mistake commonly made is when either the
RNA or protein content differential expression is compared. This comparison can’t be
made since there is no mechanism to properly normalize the content. Currently, either
total RNA or protein is used for-omic wide analysis. Comparisons using PCR commonly
use standard house keeping genes such as GAPDH or β-actin. An alternative approach
could try to normalize expression based on a standardized approach that takes cell
number and exosome secretion into account, however, making direct comparisons
utilizing this approach still might not solve this issue because you would still be
comparing two different biological entities.
A fundamental limitation of this study concerns the exosome isolation approach.
This pitfall is still the most significant challenge facing the exosome field in general.
Essentially, due to the overlap in size and exosome lipid bilayer, isolation approaches
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based on size exclusion or buoyant density fail to isolate pure exosome populations.
Complicating the issue, density gradients assessing protein and RNA content in different
density layers are reporting tremendous overlap (289). Future approaches have been
suggested to identify exosome specific cargo and generate affinity-based isolation
methods. Currently, a panel commissioned by the Journal of Extracellular vesicles
proposed harvesting exosomes using a discontinuous density gradient and running
downstream assays in parallel using vesicles from the different density layers (289). As
you can imagine, this approach would be incredibly tedious, but may be necessary to
better understand the molecular content and role of exosomes.
During the characterization of our normoxic and hypoxic exosomes, we identified
a diverse RNA and protein profile that may contribute to the functional differences
observed between normoxic and hypoxic exosomes. Analysis of our HypoxicEXO content
revealed elevated levels of EWS-FLI1 RNA and significantly increased EWS-FLI1, EZH2
and CD99 protein expression. Future studies will implement knockdown approaches to
determine the role of this RNA and protein profile on HypoxicEXO mediated sphere
formation and other oncogenic processes. Future work will explore and elucidate the role
of other hypoxically regulated miRNAs. Furthermore, the RNAs identified targeting the
Akt signaling axis will be examined closely to determine if a single RNA or more likely,
an intricate network of RNAs influence Akt activity. Clinically, more studies are needed to
match patient serum exosome content with their parental tumor in order to enhance
detection and development of better therapies for aggressive tumors.
Our findings showing HypoxicEXO increase sphere and tumor formation in EWS
cells has promising implications towards better understanding CSC biology within a
hypoxic TME. Importantly, an in vivo limiting dilution assay is needed to determine an
exosomal effect on generating CSCs or mediating dedifferentiation of non-tumor forming
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EWS cells into tumor-initiating cells. This approach combined with FACS analysis will
help identify cells susceptible to cellular reprogramming. A likely pitfall is that hypoxia
and HypoxicEXO a mediating a stem-like phenotype and given these cell lines are
immortalized, will never truly reflected the CSC phenotype observed in primary cells.
Alternatively, isolating patient serum and co-culturing patient derived exosomes with
cells harvested from their parental tumor is needed to confirm the physiological
importance of our study.
The use of siRNAs and miRNA mimics and inhibitors in our work limits the impact
of our findings due to their transient effects. Future work implementing lentiviral
mediated overexpression, knockdown or knockout methods will provide stable genetic
manipulation. Stable overexpression or knockdown of HIF-1α, miR-210 and CASP8AP2
is needed in the future to determine the role of these molecules in sphere formation.
Importantly, stable transduction is needed in sphere assays because of the long
incubation times and the effects of transient transduction are difficult to determine. In
addition, stable knockdown of HIF-1α will help determine the hypoxia dependent and
independent effects of Akt on miR-210 expression and the downstream effects on
survival mechanisms in hypoxic cells.
Lastly, our observations showing HypoxicEXO can reprogram NIH3T3 cells and
increase tumorigenicity presents a new role for exosomes within the TME. Our findings
demonstrating HypoxicEXO increase Akt signaling in transformed CAFs and Akt activation
may underly the observed tumorigenic effects. Future work will identify and confirm
miRNA involved in activating the Akt signaling axis. In addition, given HypoxicEXO are
carrying elevated levels of EWS-FLI1 transcript and protein, future studies with FLAG
tag EWS-FLI1 and look for stable expression within the NIH3T3 cells exposed to
HypoxicEXO.
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Analysis of Pitfalls in EWS Hypoxia Studies
Early in my research, I encountered many pitfalls when I began conducting my
hypoxia experiments. Current studies investigating the role of hypoxia in EWS contain
tremendous contradictions with work done by hypoxia experts in other fields. Here, I
wanted to highlight and critique these pitfalls in EWS hypoxia research and provide the
logical rationale that led to my approach to studying hypoxia in EWS.
Hypoxia research investigating the temporal expression of the HIFs have
encountered conflicting and often paradoxical results that can largely be attributed to
previously mentioned variables such as cell type, severity of hypoxic conditions and
duration, culture conditions and proper control of both HIF-1α and HIF-2α during
interpretation of results. An additional challenge to hypoxia research lies in the technical
challenges of harvesting cells once they have been removed from their hypoxic
environment. HIFs undergo proteasomal degradation within minutes and must be
processed quickly on ice followed by snap freezing in liquid nitrogen to preserve the
intact HIF protein. In addition, the use of polyclonal antibodies will detect the intact 120
kDa HIF proteins as well as the degraded 90 kDa forms which are present under
normoxia. Special attention must be paid to the different molecular weights when using
polyclonal antibodies against the HIFs, however, commercial monoclonal antibodies only
detect the 120 kDa form. One must always be skeptical of studies reporting HIF
expression under normoxic conditions, however, loss of function mutations in HIF
regulatory proteins or upregulation of miRNAs targeting HIF regulators in context
dependent models would provide the obvious caveat to this problem. The use of hypoxia
mimetics introduces another confounding variable that is mainly used as a control or as
a replacement for hypoxia reducing the technical challenges associated with hypoxic
cells. A common mimetic used is CoCl2, this mimetic stabilizes the HIFs by inhibiting
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PHD enzymatic hydroxylation of the HIF proline residues through replacement of Fe with
Co resulting in stable HIF expression (143). This approach has largely been deemed
acceptable by the field when employed as a positive control for HIF analysis, and certain
considerations should be taken into account when using this techniques since HIF
regulation is finely tuned under hypoxia and the mimetics might produce results not seen
in a hypoxic environment.
In EWS hypoxia research, observations of the temporal expression of HIF-1α and
HIF-2α have been limited where many studies focus primarily on HIF-1α without
accounting fof HIF-2α. In addition, all of these studies have implemented the various
approaches previously mentioned leading to conflicting outcomes between studies. The
first study in EWS investigated the effects of hypoxia on apoptosis, here they observed
that hypoxic EWS cells cultured under severe hypoxia (<0.1% O2) were resistant to
apoptosis. HIF-1α expression was observed at 6 hrs and steadily increased over a 72 hr
period (144). This observation has been supported in other studies conducting
experiments under severe hypoxia (140), however, under moderate (1% O2) hypoxia,
HIF-1α normally stabilizes at 6 hrs and decreases to a lower basal expression level.
Severe hypoxia resembles necrotic regions in tumors and interestingly, is associated
with the worst overall outcome in EWS patients (142). This study revealed HIF-1α siRNA
knockdown resulted in apoptosis by downregulating the known HIF-1α target GLUT1
(144). HIF-2α also targets GLUT1 under prolonged moderate hypoxia. In this study,
severe hypoxia stabilized HIF-1α at high levels over days which probably complicated
interpretations of HIF-1α function in EWS at the time. The hypoxia mimetic CoCl2 was
used in a limited capacity as a positive control in this study (144).
The seminal EWS hypoxia study was conducted by Aryee et al in 2010, here
they were the first to report the expression of HIF-1α in primary EWS tumors and the
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effect of hypoxia on EWS-FLI1 expression (143). In addition, they demonstrated that
hypoxia increases invasion and anchorage independent growth in EWS cell lines.
Significantly, they demonstrated that shHIF-1α knockdown resulted in decreased EWSFLI1 expression, however, these experiments were conducted under normoxic
conditions with CoCl2. They showed that EWS-FLI1 protein expression increased upon
HIF-1α stabilization, yet was unchanged at the mRNA level suggesting posttranscription
modulation of EWS-FLI1. In some of their western blots, HIF-1α expression continued to
elevate for a duration of days under moderate (1% O2) hypoxia while in other cell lines,
HIF-1α remained stable over the same period. Both of these findings are not consistent
with the temporal expression of HIF-1α reported in other studies, including our own
observations. A potential explanation may lie in inconsistent oxygen tension levels,
timely processing of the cells or in the use of the polyclonal HIF-1α antibody reported in
their methods sections (143).
Later that same year, Knowles et al. reported HIF-1α and HIF-2α expression in
EWS patient tumors along with HIF co-localization but did not discuss any association
with patient outcomes (145). Their findings demonstrating HIF-1α regulation of GLUT1
were similar to Aryee et al., however, Knowles et al. conducted their experiments under
0.1% O2 while Aryee et al. performed all of their studies at 1% O2. In addition, Knowles
et al cultured their cells under hypoxia for 24 hr. where Aryee et al. used multiple time
points. Interestingly, knockdown of HIF1α in the Knowles study revealed decreased
levels of GLUT1 and VEGFA but no difference was observed in the shHIF-2α EWS cells.
Both HIFs have been demonstrated to target these genes but under temporally different
periods of hypoxic exposure. HIF-2α is generally stabilized and active at 48 hrs which
this study failed to explore. However, they performed all of their studies under 0.1% O2
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which results in the time dependent accumulation of stable HIF-1α which would explain
the stronger effect of HIF-1α (145).
The only EWS study that has reported a HIF-1α temporal expression pattern
consistent with the hypoxia field and our own findings was conducted by Tilan et al in
2013 (147). This group demonstrated HIF-1α maximal expression at 6 hrs followed by
decreased stable expression in the subsequent time points. Interestingly, the oxygen
levels in this study were 0.1% which conflicts with the observations reported by the
Knowles and Kilic labs. Future work is needed to clarify these inconsistencies in HIF
expression in hypoxic EWS cells. Additionally, the main focus of the study investigated
the effects of hypoxia on stemness in EWS cells. Here, they reported that hypoxia
increased the Aldh+ cells expressing OCT4 suggesting enrichment of a CSC
subpopulation, however, this study did not perform any sphere assays which measure in
vitro stemness (147).
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